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A B S T R A C T
Background
Asthma is a chronic disease in which inflammation of the airways causes symptomatic coughing, wheezing, and difficult breathing.
The inflammation may have different underlying causes, including a reaction to infection in the lungs. Macrolides are antibiotics with
antimicrobial and antiinflammatory activities that have been used long-term to control asthma symptoms.
Objectives
To assess the effects of macrolides for managing chronic asthma.
Search methods
We searched the Cochrane Airways Group Specialised Register up to April 2015. We also manually searched bibliographies of previously
published reviews and conference proceedings and contacted study authors. We included records published in any language in the
search.
Selection criteria
Randomised controlled clinical trials involving both children and adults with chronic asthma treated with macrolides versus placebo
for more than four weeks .
Data collection and analysis
Two reviewers independently examined all records identified in the searches then reviewed the full text of all potentially relevant articles
before extracting data in duplicate from all included studies.
Main results
Twenty-three studies met the inclusion criteria, randomising a total of 1513 participants to receive macrolide or placebo. The quality
of evidence was generally very low due to incomplete reporting of study methodology and clinical data, suspected publication bias,
indirectness of study populations, risk of bias and imprecision (because of small numbers of patients and events). Most of the included
studies reported data from patients with persistent or severe asthma, but inclusion criteria, interventions and outcomes were highly
variable.
1Macrolides for chronic asthma (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Macrolides were not found to be better than placebo for the majority of clinical outcomes including exacerbations requiring hospital
admission (odds ratio (OR) 0.98, 95% confidence interval (CI) 0.13 to 7.23; participants = 143; studies = 2; I2 = 0%) or at least
treatment with oral steroids (OR 0.82, 95% CI 0.43 to 1.57; participants = 290; studies = 5; I2 = 0%). The evidence on asthma
control (standardised mean difference (SMD) -0.05, 95% CI -0.26 to 0.15), quality of life (mean difference (MD) 0.06, 95% CI -
0.12 to 0.24) and rescue medication use (MD -0.26, 95% CI -0.65 to 0.12) was all of very low quality and did not show a benefit of
macrolide treatment. There was some evidence that macrolides led to some improvement on symptom scales (SMD -0.35, 95% CI -
0.67 to 0.02), and in lung function (forced expiratory volume in one second (FEV1): MD 0.08, 95% CI 0.02 to 0.14), although not
on all the measures we assessed. Measures of bronchial hyperresponsiveness were too varied to pool, but most studies showed no clear
benefit of macrolide over placebo. Two studies recruiting people taking regular oral corticosteroids suggested macrolides may have a
steroid-sparing effect in this population. Macrolides were well tolerated with respect to severe adverse events, although less than half
of the studies reported the outcome (OR 0.80, 95% CI 0.24 to 2.68; participants = 434; studies = 7; I2 = 0%). Reporting of specific
side effects was too patchy across studies to analyse meaningfully. As already reported in the previous versions of the systematic review,
biomarkers of asthma activity, such as sputum and serum level of eosinophil cationic protein (ECP) or sputum and serum eosinophils,
were lower in patients treated with macrolides, but this was not associated with clinical benefits.
Two within-study subgroup analyses showed a possible benefit of macrolides for non-eosinophilic asthma, but it was not possible to
investigate this further using the data available for this review.
Authors’ conclusions
Existing evidence does not show macrolides to be better than placebo for the majority of clinical outcomes. However, they may have
a benefit on symptom scales and some measures of lung function, and we cannot rule out the possibility of other benefits or harms
because the evidence is of very low quality due to heterogeneity among patients and interventions, imprecision and reporting biases.
The reviewhighlights the need for researchers to report clinically relevant outcomes accurately and completely using guideline definitions
of exacerbations and validated scales. The possible benefit of macrolides in patients with non-eosinophilic asthma based on subgroup
analyses in two of the included studies may require further investigation.
P L A I N L A N G U A G E S U M M A R Y
Should macrolides be used for chronic asthma?
Main point: Studies do not show that macrolides are better than placebo for most outcomes. There may be a benefit on symptom
scales and lung function but the latter depends on how this is measured. The evidence was very low quality so we can’t rule out the
possibility of other benefits or harms.
Background
Asthma is a chronic disease in which inflammation of the airways leads to coughing, wheezing and breathing problems. There are
probably different reasons for this inflammation and why it persists, and these may require different treatments. Infection in the lungs
may be one cause, and macrolides are a type of antibiotic that may be used long-term as a way of improving symptoms for these people.
How we answered the question
We looked for studies on adults or children with asthma who were either given a macrolide or placebo for at least four weeks to see if it
improved their symptoms and made it less likely for them to have an asthma attack, often referred to as an ’exacerbation’. We carried
out our most recent search for studies in April 2015. After finding all of the relevant studies, we pulled out information about asthma
attacks requiring hospital admission, asthma attacks that needed to be treated with oral steroids, symptom scales, asthma control,
quality of life, several measures of lung function, the need for rescue inhalers, serious side effects and measures of asthma activity in
blood and sputum.
What we found
We found 23 studies, including 16 new ones that had been published since the last search was done in 2007. Overall, just over 1500
people received either macrolide or placebo. There were a lot of problems in the way studies were described and how well they reported
data, which made us consider the evidence to be very low quality, undermining our confidence in most of the results. The studies were
quite different from each other, for example in the severity of people’s asthma, the type of macrolide they were given and the length of
the treatment period.
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Our review did not show that macrolides were better than placebo for most of the important outcomes we looked at. However, they
may have some benefits on symptom scales and lung function, and we cannot rule out the possibility that they are helpful for some
people or that they cause harm. There were no reports of serious side effects of macrolides, but 16 studies didn’t say whether or not any
occurred.
3Macrolides for chronic asthma (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
M acrolide versus placebo for chronic asthma
Patient or population: adults and children with chronic asthma
Settings: outpat ient
Intervention: macrolide
Drugs used were clarithromycin, azithromycin, roxithromycin and troleandomycin. Macrolide was given once or twice daily in most studies for between 6 and 52 weeks (median
8 weeks).
Comparison: placebo
Durat ions were calculated as weighted means of the studies included in each analysis
Outcomesa Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Placebo M acrolide
’Severe’ exacerbation - re-
quiring at least OCS
Number of people having
one or more exacerbat ions
requiring at least systemic
steroids. Classif icat ion var-
ied across studies
18 weeks
242 per 1000 208 per 1000
(121 to 334)
OR 0.82
(0.43 to 1.57)
290
(5 RCTs)
⊕©©©
very lowb,c,d
Symptom scales
10 weeks
The symptom scales used
were dif ferent across stud-
ies so it was not possible to
calculate an assumed risk
The mean symptom scales
in the intervent ion group
was 0.35 standard devia-
tions lower (0.67 lower to
0.02 lower)
- 139
(4 RCTs)
⊕©©©
very lowb,f,g,h
Asthma control
Scored f rom 0 to 6 (lower
scores indicate less impair-
ment)
The mean change in asthma
control score in the control
group was − 0.21
The mean asthma control
score in the intervent ion
group was 0.05 standard
deviations better (0.26 bet-
- 353
(4 RCTs)
⊕©©©
very lowb,e,i
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17 weeks ter to 0.15 worse)
Asthma Quality of Life
Questionnaire (AQLQ)
Scored f rom 1 to 7 (higher
scores indicate less impair-
ment)
16 weeks
The mean change on the
AQLQ scale in the control
group was 0.32
The mean AQLQ score in the
intervent ion group was 0.06
better (0.12 worse to 0.24
better)
- 389
(5 RCTs)
⊕©©©
very lowb,d,e,i
Rescue medication, puffs/
day
17 weeks
The mean rescue medica-
t ion use in the control group
was 1.08 puf f s/ day* *
The mean rescue medica-
t ion use in the intervent ion
group was 0.26 puffs/ day
lower (0.65 lower to 0.12
higher)
- 314
(4 RCTs)
⊕©©©
very lowb,e,i
FEV1 (L)
15 weeks
The mean FEV1 in the con-
trol group was 2.53 L
The mean FEV1 in the inter-
vent ion group was 0.08 L
lower (0.02 higher to 0.14
higher)
- 600
(9 RCTs)
⊕©©©
very lowb,j,i,k
Serious adverse events
(including mortality)
16 weeks
23 per 1000 22 per 1000
(6 to 79)
OR 0.96
(0.25 to 3.68)
359
(7 RCTs)
⊕©©©
very lowe,h,l
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
* * Assumed risk for cont inuous outcomes were calculated as weighted means of the scores in the control group. NB: Sutherland 2010 could not be included in the rescue
medicat ion or quality of lif e calculat ions because only mean dif ference between groups was reported; Brusselle 2013 was not included in the FEV1 calculat ion because it was
the only change score; Cameron 2012 was not included in the asthma control or quality of lif e calculat ions because it was the only study report ing absolute endpoint scores
rather than change f rom baseline
CI: conf idence interval; OCS: oral cort icosteroids; AQLQ: Asthma Quality of Life Quest ionnaire; FEV1: f orced expiratory volume in one second
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
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aTwo of the primary outcomes have not been presented. Bronchial hyperresponsiveness could not be pooled in a meta-
analysis and has been described narrat ively in the review. Steroid dose was not well reported in the studies, and there was
no data to analyse.
bClinical outcomes were poorly reported across studies, with no more than 9 out of 17 appearing in any ef f icacy analysis
(downgraded one level for publicat ion bias).
cDif ferences in the recruited populat ions and in the criteria used to def ine ’severe exacerbat ions’ (downgraded one level for
indirectness).
dConf idence intervals include an important benef it of macrolide and possible benef it of placebo (downgraded one level for
imprecision).
eUncertaint ies with randomisat ion procedures, and high risk of attrit ion bias in some studies included in the analysis
(downgraded one level for risk of bias).
f High heterogeneity of I2 = 77% mainly due to one of the cross-over studies (downgraded one level for inconsistency).
gSymptom scales were of ten unvalidated and highly variable across studies, and we chose not to pool most in a meta-
analysis using standard mean dif ferences, as this would lead to a result that would have been much more dif f icult to interpret
(downgraded one level for indirectness).
hSmall number of pat ients in the analysis; dif f icult to judge precision due to dif ferent scales (downgraded one level for
imprecision).
iStudies in the analysis recruited dif ferent populat ions with regards to severity of asthma, and one study only recruited
smokers (downgraded one level for indirectness)
jFour studies that we were unable to properly assess for risk of bias were included in this analysis (downgraded one level for
risk of bias), and we were not certain of how and when the measurement was taken in some cases.
kUncertainty in several domains across studies, but the study carrying the majority of the weight was well conducted (no
downgrade).
lSeven studies reported the outcomes but only three observed events (9 total events), leading to very wide conf idence intervals
that include important benef it and harm of macrolide treatment (downgraded two levels for imprecision).
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B A C K G R O U N D
Description of the condition
Asthma is an inflammatory disease of the airways characterised by
chronic inflammation, bronchial hyperresponsiveness and parox-
ysmal attacks of wheezing. It affects people of every age, but fre-
quently the disease occurs in childhood, especially in those who
are atopic. There are different phenotypes of the disease, includ-
ing one that recognises infection as an important factor in airway
inflammation. Current guidelines recommend tailoring asthma
treatment according to a stepwise approach, considering severity
of symptoms and response to treatment (GINA 2014).
Short-acting bronchodilators are usually effective in controlling
intermittent asthma, but persistent asthma may require anti-in-
flammatory drugs, longer-acting bronchodilators, or both. These
are usually administered directly to the lungs via inhalation or
orally with the aim of improving respiratory symptoms by reduc-
ing airways inflammation (GINA 2014). More recent therapies
include anti-leukotrienes inmild-to-moderate asthma, humanised
antibodies such as omalizumab, immunosuppressive drugs and in-
hibitors of specific pathways, which are used only in severe, treat-
ment-resistant asthma (GINA 2014; Olin 2014).
Description of the intervention
Macrolides are a class of antibiotics that are widely used in the
treatment of various infectious diseases, including respiratory tract
infections (Alvarez-Elcoro 1999). The first studies on macrolides
in patients with asthma suggested a steroid-sparing effect (Nelson
1993), while more recent reports have demonstrated an anti-in-
flammatory effect of this class of antibiotics, whereby macrolides
seem to decrease bronchial hyperresponsiveness associated with
eosinophilic inflammation (Amayasu 2000). Macrolides are effec-
tive in the long-term treatment of cystic fibrosis, diffuse panbron-
chiolitis and chronic obstructive pulmonary disease, and they are
not associated with an increased risk of adverse events (Cai 2011;
Spagnolo 2013).
However, a potential drawback of longer-term antibiotic use for
asthma is the development of bacterial resistance by strains that
normally colonise the airways. Macrolide use in healthy volunteers
led to pharyngeal carriage of macrolide-resistant streptococci (
Malhotra-Kumar 2007), which is of particular concern for the
wider community.
How the intervention might work
Macrolides have anti-inflammatory and antimicrobial properties
that may improve asthma symptoms in two ways: by reducing air-
ways inflammation directly and by controlling intracellular infec-
tion, which may trigger and maintain inflammation (Black 1997;
Black 2000; Kawasaki 1998). Their anti-inflammatory potential
has been linked to their action on pro-inflammatory cytokines
that cause inflammation, which was highlighted by the results of
the previous versions of this systematic review (Richeldi 2002;
Richeldi 2005). In vivo and in vitro studies of human and animal
models have demonstrated that macrolides suppress the produc-
tion of cytokines such as interleukins and inhibit the neutrophil
adhesion to epithelial cells, the respiratory burst of neutrophils
and the secretion of mucus from human airways (Adachi 1996;
Konno 1994; Koyama 1998).
The potential benefit of their antimicrobial action for people with
asthma was suggested after observational studies identified intra-
cellular bacterial infection (i.e.Chlamydophilia pneumoniae orMy-
coplasma pneumoniae) as a possible trigger of bronchial inflamma-
tion (Kraft 1998). Gencay 2001 subsequently demonstrated that
people with asthma had a higher frequency of C. pneumoniae an-
tibodies than matched controls. Longitudinal studies showed no
clear effect of infection with C. pneumoniae on the incidence of
asthma, but patients who had an infection and developed asthma
showed a faster decline in lung function (Pasternack 2005). Fur-
thermore, in children with asthma, M. pneumoniae detection in
respiratory samples was associated with poorer asthma control
(Wood 2013). Recent studies in animal models seems to point out
an important role of the infection with C. pneumoniae in the early
phases of life in the pathogenesis of severe asthma (Essilfie 2015;
Hansbro 2014).
Why it is important to do this review
Macrolides represent a relatively inexpensive intervention thatmay
improve control of inflammation and clinical outcomes in patients
with chronic asthma.
O B J E C T I V E S
To assess the effects of macrolides for managing chronic asthma.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included parallel and cross-over randomised controlled trials
(RCT).
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Types of participants
Children and adult patients with chronic asthma.
Types of interventions
Macrolides, administered for more than four weeks, versus
placebo. We have pooled data from studies comparing different
macrolide therapies.
Types of outcome measures
Primary outcomes
• Number of exacerbations requiring hospitalisation and
severe exacerbations (requiring emergency room (ER) visits or
short-course systemic steroids)
• Asthma symptoms (including symptom scores, asthma
control scores and asthma quality of life scores)
• Asthma medication requirements (need for rescue
medications)
• Lung function, including morning and evening peak
expiratory flow (PEF) and forced expiratory volume in one
second (FEV1)
• Non-specific bronchial hyperreactivity (to histamine or
methacholine)
• Lowest tolerated oral corticosteroid dose (in patients
requiring oral corticosteroids at baseline)
Secondary outcomes
• Number and type of side effects
• Number of study withdrawals
• Eosinophil count in peripheral blood samples, sputum
samples or both
• Eosinophilic cationic protein (ECP) measurements in
serum and in sputum.
Search methods for identification of studies
Electronic searches
Search methods used in the previous version of this review are
detailed in Appendix 1. The previously published version included
searches up toMay 2007. The search period for this update isMay
2007 to April 2015.
Trials were identified using the Cochrane Airways Group Spe-
cialised Register, which is maintained by the Trials Search Co-
ordinator for the Group. The Register is derived from systematic
searching of electronic databases including the Cochrane Cen-
tral Register of Controlled Trials (CENTRAL), MEDLINE, EM-
BASE and CINAHL, and handsearching of respiratory journals
andmeeting abstracts (see Appendix 2 for more details). Appendix
3 describes the search strategy used in the Specialised Register.
We also searched ClinicalTrials.gov (www.clinicaltrials.gov) and
the WHO trials portal (www.who.int/ictrp/en/). We searched all
databases from their inception to April 2015, with no restriction
on language of publication.
Searching other resources
We surveyed review articles and bibliographies identified from the
primary papers for additional references and RCTs.
Data collection and analysis
Selection of studies
Two reviewers (KK and GF) independently screened the abstracts
of articles identified using the search strategy above, retrieving the
full text for articles that appeared to fulfil the inclusion criteria.
Two reviewers independently reviewed and categorised each article
identified as included or excluded (KK and GF). When there was
disagreement or doubt, a third reviewer (KU) assessed the article
and helped to reach a consensus.We presented a PRISMAdiagram
to illustrate the flow of studies through the selection process (
Moher 2009).
Data extraction and management
We used a data collection form to collect study characteristics and
outcome data. We piloted the form on at least one study in the
review. Two review authors (KK and GF) extracted the following
study characteristics from included studies, when available.
1. Methods: study design, total duration of study, details of
any run-in period, number of study centres and location, study
setting, withdrawals and date of study.
2. Participants: n, mean age, age range, gender, severity of
condition, diagnostic criteria, baseline lung function, smoking
history, inclusion criteria and exclusion criteria.
3. Interventions: intervention, comparison, concomitant
medications and excluded medications.
4. Outcomes: primary and secondary outcomes specified and
collected, and time points reported.
5. Notes: funding for trial, and notable conflicts of interest of
trial authors.
Two review authors (KK and IK) independently extracted outcome
data from included studies. We noted in the ’Characteristics of
included studies’ table if outcome data was not reported in a usable
way. We resolved disagreements by involving a third person (KU).
One review author (KK) transferred data into the ReviewManager
(RevMan) file. Two reviewers (GF and KU) double-checked that
data were entered correctly by comparing the data presented in
the systematic review with the study reports.
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Assessment of risk of bias in included studies
Two review authors (KK and GF) independently assessed risk of
bias for each study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We resolved disagreements by discussion and by involving another
author (KU). The risk of bias was assessed according to the fol-
lowing domains.
1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective outcome reporting.
7. Other bias.
Each potential source of bias was graded as high, low or unclear
and justified with a quote from the study report in the ’Risk of
bias’ table. The risk of bias judgements across different studies
were summarised for each of the domains listed. Blinding was
considered separately for different key outcomes where necessary
(e.g. for unblinded outcome assessment, risk of bias for all-cause
mortality may be very different than for a patient-reported pain
scale). Where information on risk of bias related to unpublished
data or correspondence with a trialist, we noted this in the ’Risk
of bias’ table.
When considering treatment effects, the risk of bias for the studies
that contribute to that outcome were taken into account.
Measures of treatment effect
We analysed dichotomous data as odds ratios (OR) and continu-
ous data as mean difference (MD) or standardised mean difference
(SMD). We entered data presented as a scale with a consistent
direction of effect. We narratively described skewed data reported
as medians and interquartile ranges. We analysed data from cross-
over trials using generic inverse variance (GIV). We pooled results
from cross-over trials and parallel trials. Where raw data and ad-
justed analyses (e.g. accounting for baseline differences) were pre-
sented in the same trial, we used the latter.
We undertook meta-analyses only wheremeaningful, that is, if the
treatments, participants and the underlying clinical question were
similar enough for pooling to make sense.
Where multiple trial arms were reported in a single trial, we in-
cluded only the relevant arms. If two comparisons (e.g. drug A
versus placebo and drug B versus placebo) were combined in the
same meta-analysis, we halved the control group to avoid double-
counting.
If change from baseline and endpoint scores were available for
continuous data, we used change frombaseline unless themajority
of studies reported endpoint scores. If a study reported outcomes
at multiple time points, we used the end-of-study measurement.
When both an analysis using only participants who completed the
trial and an analysis that imputed data for participants who were
randomised but did not provide endpoint data (e.g. last observa-
tion carried forward) were available, we used the latter.
Unit of analysis issues
For dichotomous outcomes, we used participants rather than
events as the unit of analysis (i.e. number of adults admitted to
hospital rather than number of admissions per adult). For contin-
uous data in cross-over trials, we entered data using generic inverse
variance from suitable adjusted analyses to account for the trial’s
design.
Dealing with missing data
We assessed the potential for bias in each trial as a result of partic-
ipants dropping out of the intervention prematurely. Where this
was thought to introduce serious bias, we removed the studies in
a sensitivity analysis.
Assessment of heterogeneity
We used the I2 statistic to measure heterogeneity among the trials
in each analysis. If we identified substantial heterogeneity (e.g. I
2 greater than 30%), we reported it and performed a sensitivity
analysis with a random-effects model.
Assessment of reporting biases
Wewere not able to pool more than 10 trials for any of the primary
outcomes, so were unable to examine a funnel plot to explore
possible small study and publication biases.
Data synthesis
We used a fixed-effect model for all analyses, as we expected varia-
tion in effects due to differences in study populations andmethods.
We performed sensitivity analyses with a random-effects model.
Subgroup analysis and investigation of heterogeneity
We planned subgroup analyses based on serological response or
positivity to polymerase chain reaction (PCR) for C. pneumoniae.
Sensitivity analysis
We performed sensitivity analyses based on study quality where
appropriate.
Summary of findings table
A ’Summary of findings’ table was created using the following out-
comes: number of exacerbations requiring hospitalisation; severe
exacerbations; (requiring short-course systemic steroids); asthma
symptoms (including symptom scores, asthma control and asthma
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quality of life questionnaire, AQLQ); asthma medication require-
ments (as reliever); lung function (including FEV1 and morning
and evening PEF); nonspecific bronchial hyperreactivity; serious
adverse events and withdrawal; blood and sputum eosinophils and
ECP in serum and sputum.
We used the five GRADE considerations (study limitations, con-
sistency of effect, imprecision, indirectness and publication bias)
to assess the quality of a body of evidence as it relates to the stud-
ies which contributed data to the meta-analyses for the prespec-
ified outcomes. With the exception of serious adverse events, we
did not perform GRADE ratings on the secondary outcomes. We
used methods and recommendations described in Section 8.5 and
Chapter 12 of the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011) using GRADEpro software (Brozek
2008). We justified all decisions to down- or up-grade the qual-
ity of studies using footnotes and made comments to aid reader’s
understanding of the review where necessary.
R E S U L T S
Description of studies
Results of the search
Ninety-nine citations were identified in the literature search of
previous versions of this review up toMay 2007. Duplicate sifting
of the titles and abstracts alone identified 25 potentially eligible
studies for inclusion in the systematic review. Among them, re-
viewers were concordant in identifying seven RCTs that met the
inclusion criteria. Five of these were included in the initial ver-
sion of this review, and two new studies were added in May 2005
(Kostadima 2004; Kraft 2002).
For this updated review, the search extended to April 2015. We
identified 32 new references as well as 6 other records by search-
ing reference lists of existing meta-analyses. Five titles referring to
abstracts presented at congresses were duplicates of other studies
already included in the review, leaving 33 references for screening.
We excluded 14 based on the abstract alone and 3 after screening
the full-text of the original manuscripts, leaving 16 studies eligi-
ble for inclusion in the systematic review and meta-analyses (see
’Characteristics of included studies’; ’Characteristics of excluded
studies’). The study flow of the new included studies is presented
in Figure 1.
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Figure 1. Study flow diagram.
Included studies
For brief descriptions of the included studies, please refer to the
’Characteristics of included studies’ table. For a summary of study
characteristics and a narrative on the main results of each study,
please see Table 1 and Appendix 4.
The 23 included studies reported a great variability in type of pa-
tients (ranging from intermittent aspirin-induced asthma to se-
vere asthma), interventions (different type of macrolides, admin-
istration scheme and doses in most of the studies) and outcomes
recorded. Six studies identified in a previous meta-analysis (Tong
2014) were Chinese trials that were only listed in that country’s
biomedical databases. The authors of this review were able to con-
firm key study characteristics in order to include these studies, but
we were not able to describe their characteristics and risk of bias
in the same detail as for the 17 other included studies.
Design
All the studies were randomised controlled trials using placebo
controls, and the majority were described as double-blind. There
were 20 parallel group studies and three cross-over studies
(Amayasu 2000; Kapoor 2010; Shoji 1999). Median study du-
ration was 8 weeks (range 4 to 52 weeks). Two studies were re-
ported in the form of abstracts from congresses, with a very limited
amount of data available (Belotserkovskaya 2007; Kapoor 2010),
and six were Chinese studies for which we had only basic informa-
tion (He 2009; Wang 2012; Wang 2014; Xiao 2013; Yan 2008;
Zhang 2013).
Participants
The studies included a total of 1532 participants of which 1513
were relevant to this review (Strunk 2008 included a third group
of 18 people receiving a treatment that was not relevant). All par-
ticipants had an asthma diagnosis, which was generally established
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according to the guidelines in use at the time of the studies (ATS
1987,GINA 1995; GINA2002; GINA2007; GINA2010); these
are similar to the current international guidelines (GINA 2014).
Three studies assessed the effects of macrolide treatment in paedi-
atric asthma (Kamada 1993; Piacentini 2007; Strunk 2008), and
the rest recruited asthma patients over the age of 18 years. The
studies varied according toGINA 2014 criteria for asthma severity,
and often there was very little information about baseline severity.
Most studies included participants with persistent mild-to-severe
asthma, while one included participants with intermittent asthma
(Amayasu 2000), and one used patients with aspirin-induced in-
termittent asthma (Shoji 1999).
Three studies investigated the role of macrolides in patients with
evidence of C. pneumoniae or M. pneumoniae infection, based on
serological (Black 2001) or molecular (Kraft 2002; Sutherland
2010) methods. The presence of these co-infections or of other
concomitant co-infections was not investigated in the remaining
studies, although we could not confirm this fact in the non-En-
glish language papers. Cameron 2012 investigated the effect of
macrolides in adult smokerswith persistent asthma,while Brusselle
2013 and Simpson 2008 considered the effect of macrolides in
patients with severe non-eosinophilic asthma.
Interventions
Five studies compared roxithromycin with placebo (Black 2001;
Kapoor 2010; Shoji 1999; Xiao 2013; Yan 2008); six stud-
ies compared clarithromycin with placebo (Amayasu 2000;
Kostadima 2004; Kraft 2002; Simpson 2008; Sutherland 2010;
Wang 2014); 10 studies investigated the effect of azithromycin
(Belotserkovskaya 2007; Brusselle 2013; Cameron 2012; Hahn
2006;Hahn 2012;He 2009; Piacentini 2007; Strunk 2008;Wang
2012; Zhang 2013), and two studies assessed the effects of trole-
andomycin in addition to oral steroid therapy as part of a steroid
tapering protocol (Kamada 1993; Nelson 1993).
Outcomes
Five studies did not appear in any of the quantitative syntheses
(Belotserkovskaya 2007; Black 2001; Kapoor 2010; Wang 2012;
Zhang 2013), and two more only contributed to the bronchial hy-
perresponsiveness summary of results and withdrawal (Piacentini
2007; Simpson 2008).
Seven studies considered exacerbations (requiring hospitalisation
or emergency room (ER) visit/systemic steroids) as an outcome,
but the definition of ’severe’ exacerbation was variable and some-
times unclear (Amayasu 2000; Brusselle 2013; Cameron 2012;
Hahn 2012; Kostadima 2004; Strunk 2008; Sutherland 2010).
Tong 2014 did not include exacerbations as an outcome but ex-
plicitly confirmed that the Chinese studies did not report this
outcome either. Data from these studies only contributed to one
meta-analysis (FEV1). We narratively summarised data that could
not be meta-analysed for the relevant outcomes.
Most studies reported measures of symptoms, asthma control or
quality of life, but the analyses were limited by the way data were
reported and by the scales that could be reasonably pooled inmeta-
analysis. We did not consider a meta-analysis of all these measures
to be valid or the subsequent results to be interpretable in any
meaningful way, so we chose only to meta-analyse those that we
knew to be similar. Standardised mean difference had to be used
for the ’symptom scale’ meta-analysis, which still made the effect
and its precision difficult to interpret.
Four studies reported data about change in rescue medication as
puffs per day in a way that could be included in meta-analysis
(Brusselle 2013; Hahn 2012; Strunk 2008; Sutherland 2010).
Most of the studies reported measures of lung function such as
FEV1, forced vital capacity (FVC) or PEF, but only six reported
data for the same measure that could be pooled. There were some
issues with selective reporting that prevented studies from being
included in the analyses, such as data only being presented graphi-
cally or without a measure of variance (e.g. Black 2001). It was of-
ten unclear when the measures were taken, (i.e. pre- or post-bron-
chodilator), but when the information was available, we recorded
it in the analysis footnotes. Brusselle 2013 reported percentage
FEV1, but their data could not be combined with the other stud-
ies, which reported the outcome in litres. We combined the data
made available to us from Tong 2014 for He 2009, Wang 2014,
Xiao 2013 and Yan 2008, but we performed a sensitivity analysis
without them due to our uncertainties about which measures were
used and the unclear risk of bias. We were also provided with data
for peak flow for Wang 2014, Xiao 2013 and Yan 2008, but the
data were a different order of magnitude to the other studies, and
it did not make sense to pool them.
Bronchial hyperresponsiveness was considered in nine studies
(Amayasu 2000; Cameron 2012; Kamada 1993; Kostadima 2004;
Nelson 1993; Piacentini 2007; Shoji 1999; Simpson 2008;
Sutherland 2010) but there was a lot of variation in the measures
used and the way the data were reported, which meant it was not
possible to meta-analyse the data. The raw data have been pre-
sented in a table with information about the measures used.
Adverse events were considered in most of the studies, but serious
adverse events were only explicitly reported as an outcome in seven
(Amayasu 2000; Brusselle 2013; Cameron 2012; Hahn 2006;
Hahn 2012; Kamada 1993; Sutherland 2010). While it was not
ideal to include the dichotomous cross-over datawithout adjusting
them to account for matched pairs, no events were observed in
Amayasu 2000, so it did not contribute to the pooled effect.
Nine studies (Brusselle 2013; Hahn 2006; Hahn 2012; Kamada
1993; Kostadima 2004; Nelson 1993; Simpson 2008; Strunk
2008; Sutherland 2010) reported study withdrawal.
Eight studies reported the effect of macrolides on markers of in-
flammation related to asthma activity (Amayasu 2000; Cameron
2012; Kraft 2002; Nelson 1993; Piacentini 2007; Shoji 1999;
Simpson 2008; Yan2008), but they used differentmeasures, which
could not be pooled in one analysis. There were also some issues
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with data accuracy or incomplete reporting that reduced our con-
fidence in the reliability of the data. The separate analyses include
very small participant numbers, mostly from the two cross-over
studies.
Two studies considered the steroid-sparing effect of macrolides
(Kamada 1993; Nelson 1993).
Excluded studies
We excluded three studies after viewing the full papers. One is an
ongoing study (ACTRN12609000197235), one a commentary
rather than an RCT (Anon 2009), and one was a paediatric trial
that was too short (less than four weeks as set out in the protocol)
to be included (Koutsoubari 2012).
We excluded 18 studies after viewing the full texts in the previous
version of this review. The most common reason for exclusion was
that the study was not a randomised controlled trial (n = 9). We
excluded four studies due to the short length of the study period,
two because they were in vitro studies, two because the patients
did not have asthma and one because it had been terminated prior
to completion.
Risk of bias in included studies
There was considerable uncertainty relating to study methodology
due to insufficient reporting in the published reports. This was
particularly true for the selection bias domains, but also for blind-
ing of outcome assessment and attrition bias. We had concerns
about incomplete and selective reporting of the results for most
of the studies and generally considered there to be a high risk for
publication bias because only a small number of studies reported
data in a way that could be pooled in meta-analysis. Summaries of
the risk of bias judgements for each study are presented in Figure
2 and Figure 3.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Pharmaceutical industries financed at least five included stud-
ies (Amayasu 2000; Cameron 2012; Hahn 2006; Hahn 2012;
Kamada 1993); we could not ascertain this in the non-English
language papers. The authors of Tong 2014 provided us with in-
formation about study quality for the studies that were not avail-
able in English.
Allocation
We deemed 11 studies to be at low risk of bias for random se-
quence generation, including five of the English language stud-
ies (Brusselle 2013; Hahn 2006; Hahn 2012; Piacentini 2007;
Simpson 2008) and six that were awarded two points using the
Jadad scoring system (Jadad 1996) in Tong 2014. For the rest,
allocation bias was unclear.
Only 3 studieswere at low risk for adequate allocation concealment
(Brusselle 2013; Hahn 2006; Hahn 2012); the 6 studies from the
Tong 2014 review were not assessed for this criterion because it is
not considered in the Jadad system, so we had to rate those studies
as unclear, and the 14 other studies did not adequately describe
the methods used.
Blinding
Most of the studies being described as double-blind and placebo-
controlled contained adequate descriptions of the blinding of pa-
tients andpersonnel, butmethodswere unclear in eight studies (in-
cluding two in an abstract form: Belotserkovskaya 2007; Kapoor
2010). We rated one study as having a high risk of bias (Strunk
2008).
Blinding of outcome assessment was mostly unclear and only
judged to be adequate in six studies (Cameron 2012; Hahn 2006;
Hahn 2012; Kraft 2002; Piacentini 2007; Sutherland 2010). The
same study that we rated high for performance bias also carried a
high risk for detection bias (Strunk 2008).
Incomplete outcome data
Five studies had a high risk of attrition bias (Hahn 2006; Hahn
2012; Kostadima 2004; Nelson 1993; Sutherland 2010) and 5
others carried a low risk (Black 2001; Brusselle 2013; Kraft 2002;
Simpson 2008; Strunk 2008), while the risk was unclear for the
other 13 other studies.
Selective reporting
We judged eight studies (Belotserkovskaya 2007; Black 2001;
Cameron 2012; Kamada 1993; Kapoor 2010; Simpson 2008;
Strunk 2008; Sutherland 2010) to be at high risk of selective re-
porting. This was mostly due to insufficient reporting of numeri-
cal data, which meant they could not be pooled in meta-analysis.
We only considered three to be at low risk of bias (Brusselle 2013;
Hahn 2006; Hahn 2012). We rated 12 studies as unclear for this
domain, including the 6 non-English language studies, which we
could not assess fully.
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Overall, it is likely that reporting biases had a significant effect on
the completeness of the meta-analyses in this systematic review.
Other potential sources of bias
Kamada 1993 showed significant baseline imbalances between
groups, and this may have been an issue in some of the other trials
that included very small numbers of participants.
Effects of interventions
See: Summary of findings for the main comparison Macrolide
compared to placebo for chronic asthma
We present the data in order of outcomes listed in the methods.
Evidence quality was mostly very low, with most of the analyses
being downgraded for publication bias because so few studies re-
ported clinical data sufficiently well to be included in meta-analy-
sis.We also downgraded most for indirectness due to differences in
the study populations and the way outcomes were defined, and for
risk of bias due to uncertainty of randomisation procedures and
high risk of attrition bias. Appendix 4 presents a narrative on each
study, except for the six that we could not assess fully (He 2009;
Wang 2012; Wang 2014; Xiao 2013; Yan 2008; Zhang 2013).
Primary outcomes
Exacerbations requiring hospitalisation
Amayasu 2000 and Brusselle 2013 reported on exacerbations re-
quiring hospitalisation, with only four events (all recorded in the
Brusselle 2013 study, with two in the treatment and two in the
placebo group). Thus, the effect was far too imprecise to inter-
pret meaningfully (OR 0.98, 95% CI 0.13 to 7.23; participants
= 143; studies = 2; I2 = 0%; Analysis 1.1). The evidence was very
low quality, being downgraded twice for imprecision and once for
publication bias because so few studies could be included in the
analysis. Due to the small number of events, we performed a sen-
sitivity analysis using the Peto odds ratio, which did not change
the conclusions.
’Severe’ exacerbations: exacerbations requiring ER
visits/systemic steroids
Five studies reported data on ’severe’ exacerbations (Amayasu
2000; Brusselle 2013; Hahn 2006; Kostadima 2004; Strunk
2008), and none showed a benefit of macrolides over placebo (OR
0.82, 95% CI 0.43 to 1.57; participants = 290; studies = 5; I2
= 0%; Analysis 1.2). The data suggest 34 fewer people per 1000
would have an exacerbation while taking a macrolide compared
with placebo over 18 weeks, but the 95% confidence intervals
range from 121 fewer to 92 more. The evidence was very low
quality, being downgraded for publication bias, indirectness and
imprecision. It was not always clear how the studies had defined
’severe’ exacerbations, which further reduced our confidence in the
result.
Symptoms and quality of life
Symptom scales used across studies varied and were mostly not
validated. Data from four studies that could be combined inmeta-
analysis (Amayasu 2000; Hahn 2006; Hahn 2012; Kamada 1993)
suggested a modest benefit of macrolides compared with placebo
(SMD -0.35, 95% CI -0.67 to -0.02; participants = 156; studies
= 4; I2 = 77%; Analysis 1.3). We downgraded the evidence for
publication bias, risk of bias, heterogeneity, and indirectness and
imprecision, meaning it was very low quality, and we had very
little confidence in the result. We did not have information on the
scales used in the Chinese studies, so we were not able to confirm
whether they were similar enough to pool.
A meta-analysis of four studies (Brusselle 2013; Cameron 2012;
Hahn 2012; Sutherland 2010) reporting measures of asthma con-
trol, mostly the Asthma Control Questionnaire, did not show any
benefit of macrolide over placebo (SMD− 0.05, 95% CI − 0.26
to 0.15; participants = 353; studies = 4; I2 = 0%; Analysis 1.4),
and the same was true for quality of life on the Asthma Quality of
Life Questionnaire AQLQ (MD 0.06, 95% CI − 0.12 to 0.24;
participants = 389; studies = 5 (as above plus Hahn 2006); I2 =
18%; Analysis 1.5). We considered evidence for both of these out-
comes to be very low quality after downgrading it for publication
bias, risk of bias and indirectness; in addition, we downgraded the
evidence on asthma control for imprecision.
Need for rescue medications
A meta-analysis of data from Brusselle 2013, Cameron 2012,
Hahn 2006 and Sutherland 2010 did not show a difference be-
tween macrolides and placebo in reducing need for rescue medi-
cations (MD− 0.26, 95% CI− 0.65 to 0.12; participants = 314;
studies = 4; I2 = 26%; Analysis 1.6). Again, the evidence was very
low quality, being downgraded for publication bias, risk of bias
and indirectness.
Morning and evening PEF
The data for morning and evening PEF did not suggest a benefit
of macrolide over placebo, but the evidence was very low quality
(Morning PEF: MD 2.22, 95% CI − 9.73 to 14.17; participants
= 289; studies = 4; I2 = 0%; Analysis 1.7; data fromBrusselle 2013;
Cameron 2012; Kamada 1993; Sutherland 2010). Evening PEF:
MD 1.97, 95%CI− 12.68 to 16.62; participants = 212; studies =
3; I2 = 0%; Analysis 1.8; data from Brusselle 2013; Kamada 1993;
Sutherland 2010). The evidence for both measures was down-
graded due to issues with risk of bias, indirectness, imprecision and
suspected publication bias. Data for three additional studies were
provided by Tong 2014, but it was not clear if they were morning
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or evening measurements (Wang 2014; Xiao 2013; Yan 2008).
Moreover, the data were in a different order of magnitude to the
other studies and had been combined using standardised mean
difference, so we could not combine them. These three studies all
showed a benefit of macrolide over placebo, but the method of
analysis meant it was difficult to quantify.
FEV1
There was a small benefit of macrolide over placebo on FEV1 in
litres (MD 0.08, 95% CI 0.02 to 0.14; participants = 600; studies
= 9; Analysis 1.9). We deemed the evidence to be of very low
quality after downgrading it for publication bias, indirectness and
risk of bias. It was not always clear whether the measurement was
taken before or after a bronchodilator. We performed a sensitivity
analysis, removing the data included from the studies we were
unable to extract and assess ourselves, and the effect was smaller,
no longer showing a benefit of macrolide over placebo (MD 0.02,
95% CI − 0.07 to 0.11).
Bronchial hyperresponsiveness
We could not compare the results reported for bronchial hyper-
responsiveness in nine studies due to differences in the challenge
agent (e.g. methacholine, hypertonic solution) and measurement
(histamine provocative concentration causing a 20% ( PC20) or
15% (PC15) drop in FEV1, results expressed as log) in the different
studies. We present the unpooled data in Analysis 1.10. Amayasu
2000, Kostadima 2004 and Sutherland 2010 reported a signifi-
cant effect of macrolides in reducing bronchial hyperresponsive-
ness compared to placebo, while Cameron 2012, Kamada 1993,
Nelson 1993, Piacentini 2007, Simpson 2008 and Shoji 1999 re-
ported no effect compared with placebo.
Oral corticosteroid dose
Most studies either excluded patients taking oral corticosteroids
or recruited people who did not take them regularly. Two stud-
ies that recruited participants taking regular oral corticosteroids
reported that macrolides had a steroid-sparing benefit (Analysis
1.11). However, there was a baseline imbalance in corticosteroid
dose in Nelson 1993, which overstated the difference at endpoint.
We chose not to combine the study results because it was not clear
if the ways the doses were calculated were sufficiently similar for
pooling to make sense (see footnotes).
Secondary outcomes
Drug tolerability and serious adverse events
In general, macrolides were well tolerated, and there were no
recorded deaths due to treatment with macrolides. A meta-anal-
ysis of seven studies (Amayasu 2000; Brusselle 2013; Cameron
2012; Hahn 2006; Hahn 2012; Kamada 1993; Sutherland 2010)
did not show a clear difference in the likelihood of serious adverse
events in the treatment and placebo groups, but the effect was
very imprecise due to the rarity of events (OR 0.80, 95% CI 0.24
to 2.68; participants = 434; studies = 7; I2 = 0%; Analysis 1.12).
Again, we rated the evidence to be of very low quality due to very
serious imprecision in the estimate, risk of bias issues, and possible
indirectness. Due to the small number of events, we performed a
sensitivity analysis using the Peto odds ratio, which did not change
the conclusions.
Withdrawal/dropouts
Pooled data from nine studies (Brusselle 2013; Hahn 2006; Hahn
2012; Kamada 1993; Kostadima 2004; Nelson 1993; Simpson
2008; Strunk 2008; Sutherland 2010) suggested the likelihood
of withdrawal from the studies was similar between participants
taking macrolide and placebo (OR 0.95, 95% CI 0.59 to 1.52;
participants = 563; studies = 9; I2 = 0%; Analysis 1.13).
Blood and sputum eosinophils
One new study (Yan 2008) reported no difference between
macrolide and placebo in blood eosinophils, but analysed data
were only available as standardised mean difference, so we did not
enter it with the two existing studies (Amayasu 2000; Shoji 1999).
These small cross-over studies showed a reduction of eosinophils
in the blood of asthmatic patients treated with macrolides (MD−
33.50, 95% CI − 36.11 to − 30.90; participants = 62; studies =
2; Analysis 1.14). Cameron 2012, another new study, investigated
the effect of macrolides in sputum eosinophils in current smokers
with asthma, and it showed a vastly different result from the two
trials previously included in the analysis. The highly significant
heterogeneity suggested that there was a data error (I2 = 98%). For
this reason, data for the three studies have been displayed but not
pooled (Analysis 1.15).
Serum and sputum ECP
No new data were added by the new studies included in the meta-
analysis; macrolides appear to significantly reduce the concentra-
tion of ECP both in serum (MD − 12.84, 95% CI − 15.67 to
− 10.00; participants = 62; Analysis 1.16) and sputum (MD −
1.45, 95% CI− 1.78 to− 1.11; participants = 62; Analysis 1.17),
according to previous results from two studies (Amayasu 2000 and
Shoji 1999).
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Subgroup analysis
Subgroup analysis based on serological response or positivity to
PCR for C. pneumoniae was not possible due to the scarcity and
heterogeneity of data and methods.
D I S C U S S I O N
Summary of main results
Twenty-three studies, involving a total of 1513 participants given
macrolide or placebo, met the inclusion criteria. The quality of
evidence was generally very low due to incomplete reporting of
study methodology and clinical data, suspected publication bias,
indirectness of study populations, risk of bias and imprecision
caused by small numbers of patients and events. Most of the in-
cluded studies reported data frompatients with persistent or severe
asthma, but inclusion criteria, interventions and outcomes were
highly variable.
For the most part, macrolides did not lead to better clinical out-
comes than placebo, including for exacerbations requiring hospi-
tal admission (OR 0.98, 95% CI 0.13 to 7.23; participants = 143;
studies = 2; I2 = 0%) or treatment with oral steroids (OR 0.82,
95% CI 0.43 to 1.57; participants = 290; studies = 5; I2 = 0%).
The evidence on asthma control (SMD -0.05, 95% CI -0.26 to
0.15), quality of life (MD0.06, 95%CI -0.12 to 0.24), and rescue
medication use (MD -0.26, 95% CI -0.65 to 0.12) was all of very
low quality and did not show a benefit of macrolide treatment.
There was limited evidence that macrolides led to some improve-
ment on symptom scales (SMD -0.35, 95%CI -0.67 to -0.02) and
lung function (FEV1: MD 0.08, 95% CI 0.02 to 0.14), although
not on all the measures we assessed. Measures of bronchial hyper-
responsiveness were too varied to pool, but most studies showed
no clear benefit of macrolide over placebo. Two studies recruit-
ing people taking regular oral corticosteroids suggested macrolides
may have a steroid-sparing effect in this population. Macrolides
were well tolerated with respect to severe adverse events, although
less than half of the studies reported the outcome (OR 0.80, 95%
CI 0.24 to 2.68; participants = 434; studies = 7; I2 = 0%). Report-
ing of specific side effects was too patchy across studies to analyse
meaningfully. As already reported in the previous versions of the
systematic review, biomarkers of asthma activity such as sputum
and serum ECP, sputum and serum eosinophils were lower in pa-
tients treated with macrolides, but this was not associated with
clinical benefits.
Two within-study subgroup analyses showed a possible benefit of
macrolides for non-eosinophilic asthma, but it was not possible to
investigate this further using the data available for this review.
Overall completeness and applicability of
evidence
The available data donot support any generalised use ofmacrolides
in clinical practice to improve clinical outcomes in patients with
persistent asthma, but we cannot rule out the possibility of benefit
due to several shortcomings in the evidence base. The potential
benefit ofmacrolides in selected phenotypes in particular (i.e. non-
eosinophilic asthma) is not yet confirmed.
The interpretation of the available data from the 23 RCTs in-
cluded in the present review are difficult to interpret for several rea-
sons. Firstly, four different types of macrolides were used across the
studies (roxithromycin, clarithromycin, azithromycin and trole-
andomycin), often with differences in dosage and frequency of
administration. Secondly, participants with different severities of
asthma were included: the oldest studies included participants
who were taking long-term oral steroids (Kamada 1993; Nelson
1993), which could reflect a severe population or outdated pre-
scribing practice. One study included patients with aspirin-intol-
erant asthma (Shoji 1999), one included patients with intermit-
tent allergic asthma (Amayasu 2000), and another exclusively re-
cruited smokers with asthma (Cameron 2012); all the other stud-
ies enrolled patient with mild-to-severe persistent asthma, and we
could not properly assess the patient populations of six Chinese
studies. Four studies (Black 2001; Kraft 2002; Simpson 2008;
Strunk 2008) tested participants for C. pneumoniae orM. pneumo-
niae infection, but all with different techniques and very differ-
ent results. The scarcity of data in the primary analyses precluded
any meaningful subgroup analyses to assess the possible effect of
these factors.Thirdly and perhaps most importantly, the outcomes
measured were heterogeneous; reporting of exacerbations and def-
initions for severe exacerbations varied across the studies; asthma
symptoms were recorded using a variety of non-validated scales as
well as the ACQ and AQLQ, with a great variability across the
studies. Lung function and bronchial hyperresponsiveness were
often assessed and reported using different methodologies or pa-
rameters.
Two studies showing some effect on symptoms and markers of
eosinophil inflammation were unusual both in the participants
they recruited and in their design. Both were cross-over studies,
one recruiting patients with allergic intermittent asthma (Amayasu
2000; Shoji 1999), and the other enrolling patients whose asthma
was aspirin-induced.
Only three studies investigated the role of macrolides in children
with asthma (Kamada 1993; Piacentini 2007; Strunk 2008); un-
fortunately the great variability in the interventions,measurements
and outcomes makes any firm conclusion on the role of macrolides
in children impossible. Kamada 1993 suggested a potential role
for troleandomycin as steroid-sparing agent, while Strunk 2008
seems instead to exclude any role of macrolides used in this way.
Despite these limitations, our systematic review and meta-analy-
sis did not show a benefit of macrolides over placebo on rates of
exacerbations, quality of life or participants’ need for rescue med-
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ications. As discussed, this does not rule out the possibility for
significant benefit or harm of macrolides given the shortcomings
of the evidence described above, and there may be a small bene-
fit on symptom scales and some measures of lung function. The
results of this review might change if well-designed and appropri-
ately powered RCTs are conducted, but at present the evidence is
not promising enough to support further investigation in similar
cohorts of patients. There is a suggestion that research targeted
at specific phenotypes (i.e. non-eosinophilic asthma) may be war-
ranted.
Antibiotic resistance is of increasing concern and only one in-
cluded study investigated this (Brusselle 2013), reporting that
87% of azithromycin-treated patients were colonised with ery-
thromycin-resistant streptococci, a statistically significant increase
from baseline and in comparison with the placebo group. These
results suggest that spread of resistant strain is a real concern, and
any further research should clearly measure and report resistance
as an outcome. Alongside this, the case for macrolide therapy
contributing to better outcomes in those testing positive for C.
pneumoniae orM. pneumoniae infection was mostly unconvincing
(Belotserkovskaya 2007; Black 2001; Kraft 2002; Strunk 2008;
Sutherland 2010). The number of patients testing positive was
much lower than expected in several studies, and subgroup anal-
yses were often underpowered or post hoc.
Quality of the evidence
The overall quality of the evidence is very low. We had serious
concerns about publication bias and underreporting or variation
of study results; there was a lot of uncertainty regarding allocation
procedures and blinding of outcome assessment, and all but three
of the trials recruited fewer than 100 people.
We downgraded most of the analyses for publication bias because
so few studies reported clinical data well enough to be included
in meta-analysis. Some studies reported outcomes of interest but
not in a format that allowed the data to be combined with other
studies, and other studies focused on non-clinical outcomes when
the use of macrolides was being tested to assess their mechanism of
action and effect on biomarkers. Most outcomes were also down-
graded for indirectness because some studies focused on specific
populations, such as smokers or those with asthma of a particular
severity, which varied across studies. Inconsistencies in the scales
used or description of outcomes also made it difficult to meta-
analyse the data and reduced our confidence in the conclusions
that could be drawn. Risk of bias was also an issue across most of
the analyses, largely due to uncertainty as a result of insufficient
reporting of methodology, but also as a result of failure to prevent
or account for high or unbalanced dropout.
Evidence for outcomes such as exacerbations requiring hospital-
isation and serious adverse events was very imprecise due to the
length of the studies and the rarity of this sort of events, so it was
difficult to reach meaningful conclusions for these outcomes. For
other outcomes such as symptoms, quality of life and FEV1, the
reporting made it difficult for us to assess the amount of variation
in scales, properties, time of measurement, etc., and this uncer-
tainty made the data difficult to interpret.
Potential biases in the review process
We did not contact most trial authors to obtain unpublished data
or to clarifymethodology.Only nine of the studies were conducted
in the last five years, and seven were conducted over 10 years
ago. We judged that the time taken to contact all authors and the
anticipated low response rate due to study age would delay the
publication of this update.
We found six studies listed in an existing systematic review con-
ducted in China (Tong 2014) that did not appear in our searches.
While we did not limit our searches by language, they did not
cover studies that are indexed in non-English language databases.
Since the Tong 2014 systematic review was published in English,
we were able to contact the authors and extract sufficient informa-
tion to confirm the eligibility of these trials. However, we did not
have the resources to personally extract data or assess for risk of bias
in these studies, and the information we were able to include were
kindly provided by the authors of that systematic review and not
directly from the studies themselves. The review authors were able
to answer questions we had about outcomes the studies and their
outcomes, but these studies could not be assessed as rigorously as
the other 17 included studies and we could not be certain that all
of the data relevant to this review were included. For peak flow
and blood eosinophils, some of these studies could not be pooled
with the others because a different unit of analysis had been used.
In these cases we reported the results alongside the meta-analysis
results narratively. The main benefit of including these studies is
the completeness of the evidence base, and checking study lists
of existing meta-analyses is part of the standard search procedures
for Cochrane reviews. Subtle differences in the methods between
our own review and that of Tong 2014 (e.g. the way data were ex-
tracted, application of trial eligibility criteria) may also have intro-
duced a potential bias, meaning we cannot be sure that all studies
relevant to our review were picked up and analysed in the same
way. We considered the overall benefit of inclusion to outweigh
the potential biases in light of the help provided to us byHon Fang
and the other authors of that review (Fan 2015 [pers comm]).
Current methodology has enriched this updated review. These
changes, including the use of the Cochrane ’Risk of bias’ tool
rather than Jadad (Jadad 1996) and the introduction of GRADE,
resulted in differences to the original protocol but should nonethe-
less reduce the possibility for internal biases.
Agreements and disagreements with other
studies or reviews
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Two other recent meta-analyses have evaluated the treatment of
asthma with long-term macrolides (Reitner 2013; Tong 2014).
There are noticeable differences across all three in the conclusions
drawn, and this is likely a reflection of the choice of outcomes
and methods of analysis. In particular, we chose not to pool re-
sults where we were uncertain of scale or measurement similar-
ity in order to make the results as clinically meaningful as possi-
ble. Furthermore, more subtle differences in the eligibility criteria
and the way scores were aggregated are likely to have contributed
to differences in the results and conclusions, such as using stan-
dardised mean difference or mean difference, fixed or random ef-
fects, change from baseline or endpoint scores, merging multiple
relevant study arms, etc. These differences entail difficulties with
meta-analysing and interpreting the body of evidence, which is
quite heterogenous.
The analysis by Reitner 2013 included 12 RCTs with a minimum
durationof threeweeks, and reported a positive effect ofmacrolides
on symptoms scores, quality of life, peak flow and bronchial hy-
perresponsiveness. Tong 2014 included 18 studies, including the
6 Chinese studies that were not identified by our search, and it re-
ports a positive effect on several measures of lung function (FEV1,
PEF, FVC) and airways hyperresponsiveness, but not on other
measures of lung function (percentage predicted FEV1 and FVC),
symptoms, or quality of life. Neither review formally assessed ex-
acerbations, either because they were not included as an outcome
(Tong 2014) or because the data were considered insufficient to
do so (Reitner 2013). The lack of exacerbation data is a major
shortcoming of the evidence base, considering that reducing the
frequency of asthma exacerbations is the main premise of long-
term macrolides treatment.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Existing evidence does not show that macrolides are better than
placebo for most clinical outcomes. They may have a benefit on
symptom scales and some measures of lung function, and we can-
not rule out the possibility of other benefits or harms because the
evidence is of very low quality due to heterogeneity among pa-
tients and interventions, imprecision and reporting biases.
Implications for research
The review highlights the need for researchers to report clinically
relevant outcomes accurately and completely using guideline def-
initions of exacerbations and validated scales. The possible bene-
fit of macrolides in patients with non-eosinophilic asthma based
on subgroup analyses in two of the included studies may require
further investigation.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Amayasu 2000
Methods Design: randomised controlled, double-blind, placebo-controlled, cross-over study
Statistical analysis: Student’s paired T-test
Duration: 8 weeks per treatment with 4-week washout
Conducted in Yokohama, Japan, and Boston, USA
Participants Population: 17 participants were randomised to the two treatment sequences (clar-
ithromycin-placebo and placebo-clarithromycin)
Baseline characteristics: reported for population as a whole, since the study was a cross-
over design
% male: 52.9
Mean age: 38.5
% on maintenance ICS: 0
% on maintenance LABA/ICS: 0
Mean % predicted FEV1: 76.2
Mean daily ICS dose, µg: 0
Chlamydophila infection: not reported
Inclusion criteria: non-smokers, aspirin tolerant, with mild or moderate asthma di-
agnosed according to the criteria of the American Thoracic Society. All were in stable
condition and had been free of symptoms for respiratory infections for at least 6 weeks
Exclusion criteria: patients using oral or inhaled corticosteroids, theophylline, any anti-
leukotriene drug, any other anti-inflammatory agents or clarithromycin
Interventions Run-in: wash-out period of at least 4 weeks between cross-over
Intervention: clarithromycin 200 mg twice a day
Control: matching placebo
Outcomes Blood eosinophils, blood neutrophils, serum ECP, sputum eosinophils, sputum neu-
trophils, sputum ECP, symptom score, FVC, FEV1, methacholine challenge
Notes Funding: Aoki International Co, Ltd
Study ID(s): not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomly assigned, no details
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Placebo of identical appearance used; de-
scribed as double-blind
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Amayasu 2000 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No mention of dropouts
Selective reporting (reporting bias) Unclear risk Reported outcomes could be used in analy-
sis, but unclear if others were missing (pro-
tocol registration not reported)
Other bias Low risk None noted
Belotserkovskaya 2007
Methods Design: parallel randomised trial (blinding and type of control unclear)
Duration: 8 weeks
Location unclear
Participants Population: 51 adult participants with chronic stable asthma were randomised to
azithromycin (28) or ’control’ (23)
Baseline characteristics: none reported
Inclusion criteria: adults with chronic stable asthma. No other details.
Exclusion criteria: not described
Interventions Run-in: 24 week open-label period before randomisation
Intervention: azithromycin (dose not reported)
Control: ’control’ not described
Outcomes FEV1 and PEF (not suitable for analysis)
Notes Funding: not stated
Study ID(s): not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Abstract only, no information
Allocation concealment (selection bias) Unclear risk Abstract only, no information
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No mention of blinding
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Belotserkovskaya 2007 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No mention of blinding
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Number of withdrawals not given
Selective reporting (reporting bias) High risk No full text found; minimal information
about methodology and no analysable re-
sults
Other bias Low risk None noted
Black 2001
Methods Design: parallel randomised, double-blind, placebo-controlled, multicentre, multina-
tional study
Duration: 6 weeks of treatment with 24 week follow-up
Conducted in Australia, New Zealand, Italy and Argentina
Participants Population: 219 asthmatic participants were randomised to roxithromycin (105) or
placebo (114)
Baseline characteristics
% male: roxithromycin, 44.8; placebo, 50.0
Mean age (SD): roxithromycin, 40 (11.6); placebo, 42 (11.9)
% on maintenance ICS: roxithromycin, 77.1; placebo, 84.2
% on maintenance LABA/ICS: not reported
Mean % predicted FEV1 (SD): roxithromycin, 79.0 (19.3); placebo, 75.3 (17.4)
Mean daily ICS dose, µg: not reported
Chlamydophila infection: reported according to serological tests
Inclusion criteria: 18 to 60 years of age, physician diagnosis of asthma, FEV1 at least
50% of predicted and either > 15% increase in FEV1 following inhaled salbutamol or a
> 15% diurnal variation in PEF on 7 of 14 days during the run-in period. Participants
also needed to have IgG titres to C. pneumonia > 1:64,or IgA titres > 1:16, and a daytime
symptom score of at least 2 or nighttime symptom score of at least 1, on 7 of the 14 days
of the run-in period
Exclusion criteria: Treatment with any macrolide, quinolone or tetracycline in the 4
weeks before study entry or over more than 3 weeks in the preceding 4 months. Other
medicines that were not permitted were ergot alkaloids, terfenadine and astemizole.
Patients also excluded if they had a smokinghistory of >20pack-years, bronchiectasis, any
other serious systemic diseases, hypersensitivity to macrolides or any significant change
in asthma medication in the previous month, including a course of oral corticosteroids.
In addition, they were not eligible if they had a respiratory tract infection during the
run-in or if they had abnormal liver function tests or serum creatinine > 200 µmol/L
Interventions Run-in: 2 weeks
Intervention: roxithromycin 150 mg twice a day
Control: matching placebo
Treatments for asthma other than oral corticosteroids were permitted if the dose had not
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Black 2001 (Continued)
changed in the previous month
Outcomes Symptoms, PEF, FEV1, reliever medication
Notes Funding: not stated
Study ID(s): not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised but methods not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as double-blind, with matching
placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk The analysis was on an intention-to-treat
basis. This did not include 12 patients who
withdrew from the study within a few days
of randomisation, without recording any
diary card data, or a thirteenth subject who
was withdrawn because of nausea and vom-
iting and did not record any diary card data
after the first 10 days of treatment. Does
not state from which groups but represents
less than 6% of overall population
Selective reporting (reporting bias) High risk Outcomes were poorly reported. FEV1,
PEF morning and evening, symptoms and
quality of life all reported without variance
Other bias Low risk None noted
Brusselle 2013
Methods Design: parallel, randomised, double-blind, placebo-controlled, multicentre study
Duration: 26 weeks
Locations not described in details; appears to be mostly conducted Belgium
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Brusselle 2013 (Continued)
Participants Population: 109 participants were randomised to azithromycin (55) and placebo (54)
Baseline characteristics
% male: azithromycin, 47; placebo, 30
Median age: azithromycin, 53; placebo, 53
% on maintenance ICS: not reported
% on maintenance LABA/ICS: azithromycin, 100; placebo, 100
Mean % predicted FEV1 (SD): azithromycin, 80.1 (21.9); placebo, 84.8 (20.7)
Mean daily ICS dose, µg: azithromycin, 2000; placebo, 2000
Chlamydophila infection: not reported
Inclusion criteria:
18 to 75 years of age; diagnosis of persistent asthma; history consistent with Global
Initiative for Asthma step 4 or 5 clinical features; received high doses of ICS (≥ 1000
mg fluticasone or equivalent) plus inhaled LABA for at least 6 months prior to screening
and had at least two independent severe asthma exacerbations requiring systemic cor-
ticosteroids, LRTI requiring antibiotics or both within the previous 12 months; never
smokers or ex-smokers with a smoking history of≤ 10 pack-years; FeNO level was below
the upper limit of normal
Exclusion criteria: Prolonged corrected QT interval, severe bronchiectasis, significant
medical conditions or significant laboratory abnormalities that might interfere with the
study conduct or patient’s safety, pregnancy or breastfeeding, prohibited concomitant
medication including anti-IgE treatment and treatmentwithmacrolide antibioticswithin
the last 3 months
Interventions Run-in: 2 weeks
Intervention: azithromycin 250 mg per day for 5 days and then 1 capsule 3 times a week
Control: matching placebo
All patients received high-dose combination therapy of ICS and LABA for at least 6
months prior to study entry and continued this treatment throughout the study
Outcomes ACQ, AQLQ, rescue medication use, FEV1, morning and evening PEF, adverse events,
withdrawals
Severe asthma exacerbations were defined as deterioration in asthma leading to at least
one of the following: hospitalisation, emergency room visit, or need for systemic corti-
costeroids for at least 3 days
Notes Funding: academic trial, no industry funding. Agency for Innovation by Science and
Technology
Study ID(s): NCT00760838
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomly assigned in a 1:1 ratio to re-
ceive add-on treatment with azithromycin
or placebo using a central web-based ran-
domisation tool
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Brusselle 2013 (Continued)
Allocation concealment (selection bias) Low risk Web-based randomisation and the conceal-
ment of allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind design (presumably partici-
pants and investigators)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout in both groups, but higher in
placebo (3.6% vs 9.3%). ITT analysis used
Selective reporting (reporting bias) Low risk All outcomes stated in the prospectively
registered protocol were well reported
Other bias Low risk None noted
Cameron 2012
Methods Design: parallel, randomised, double-blind, placebo-controlled trial
Duration: 12 weeks
Conducted at 2 hospitals in the UK
Participants Population: 77 participants were randomised to azithromycin (39) and placebo (38)
Baseline characteristics
% male: azithromycin, 51.3; placebo, 44.7
Mean age (SD): azithromycin, 46.4 (8.8); placebo, 42.8 (9.4)
% on maintenance ICS: azithromycin, 89.7; placebo, 81.6
% on maintenance LABA/ICS: azithromycin, 38.5; placebo, 47.4
Mean % predicted FEV1: 78.3 (pre-bronchodilator)
Mean daily ICS dose, µg (SD): azithromycin, 603 (457); placebo, 709 (564)
Chlamydophila infection: not reported
Inclusion criteria: All subjects were aged 18 to 70 years, were current smokers (≥ 5 pack-
years history) with chronic asthma (> 1 year duration) and had been free of exacerbations
and respiratory tract infections for at least 6 weeks. Able to maintain asthma without
exacerbations during run-in period and able to wean off other asthma medication
Exclusion criteria: Ex-smokers or never smokers; planning to quit smoking during du-
ration of trial; patients with unstable asthma; patients with current epilepsy, psychosis or
history of significant atrial or ventricular tachyarrhythmia; corrected QT interval greater
than 450 ms in women or 430 ms in men; low potassium levels (if this can be corrected,
screening can continue with confirmation of normal levels prior to taking study med-
ication); liver disease (levels for ALT, AST or both 2 or more times ULN); significant
renal disease (creatinine or urea levels 2 or more times ULN); any previous severe ad-
verse reactions to macrolides; patients known to have specific IgE sensitivity or skin test
positivity to grass pollen and a history of worsening of asthma due to hay fever will not
be recruited from mid-May to the end of July; upper or lower respiratory tract infection
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Cameron 2012 (Continued)
in the 4 weeks prior to randomisation (run-in period can be prolonged in this situation
to have 4 weeks with no respiratory infection prior to randomisation); patients who re-
quire medications known to interact with azithromycin; on other immunosuppressants
or chronic antibiotics; weight under 45 kg; frequent asthma exacerbations (greater than
4) requiring OCS in the year prior to randomisation; current or past diagnosis of allergic-
bronchopulmonary-aspergillosis; pregnancy and breastfeeding; mental impairment or
language difficulties that makes informed consent impossible
Interventions Run-in: 4weeks (on inhaled corticosteroid therapy equivalent to 400 µg beclomethasone
± a LABA)
Intervention: azithromycin 250 mg per day
Control: matching placebo
Outcomes Change in ACQ, AQLQ, LCQ, diary symptom score, change in morning PEF, airways
responsiveness methacholine PC20, differential cell counts, colony counts, antibody sta-
tus, FeNO, exacerbation rates
Notes Funding: Medical Research Council UK and supported financially by NHS Research
Scotland (NRS), through the Scottish Primary Care Research Network. Study medi-
cation (budesonide Easyhalers; Orion Pharma, Newbury, UK) was purchased with an
educational grant from AstraZeneca (London, UK)
Study ID(s): NCT00852579
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised but no details of sequence
generation
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Masking: double-blind (subject, caregiver,
investigator, outcomes assessor)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Masking:double-blind (subject, caregiver,
investigator, outcomes assessor)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 6 patients dropped out, but details not
mentioned
Selective reporting (reporting bias) High risk Exacerbations were not reported in either
of the published reports. Other outcomes
were well reported at each of the stated time
points
Other bias Low risk None noted
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Hahn 2006
Methods Design: community-based, parallel multisite, double-blind, randomised, placebo-con-
trolled trial
Duration: 6 weeks of treatment; outcomes measured at 3 months
Conducted in community-based healthcare settings located in 4 US states and 1 Cana-
dian province
Participants Population: 45 participants were randomised to azithromycin (24) and placebo (21)
Baseline characteristics
% male: azithromycin, 33; placebo, 67
Mean age (SD): azithromycin, 50 (14); placebo, 45 (12)
% on maintenance ICS: azithromycin, 83; placebo, 76
% on maintenance LABA/ICS: not reported
Mean % predicted FEV1: not reported
Mean daily ICS dose, µg: not reported
Chlamydophila infection: azithromycin, 33%; placebo, 52%
Inclusion criteria: 18 or older with a diagnosis of current asthma that was persistent,
stable, and present for more than 3 months prior to enrolment. Stability was assessed
during a 2 to 3 week run-in period, during which eligible patients remained in the same
severity class (mild, moderate, or severe) and had no acute exacerbations. Documented
objective evidence for reversible airway obstruction, either spontaneously or after treat-
ment, was also required prior to randomisation, either FEV1 change of 12% (and > 200
mL) or PEF change of 25% (and > 60 L/min)
Exclusion criteria: ingestion of any macrolide, tetracycline or quinolone in the 6 weeks
before randomisation;macrolide allergy; any unstable illness or other cause for symptoms;
use of coumadin, anticonvulsants or digoxin; and pregnancy or lactation
Note: Asthma was defined as variable symptoms of wheeze, chest tightness, cough, or
shortness of breath triggered by a variety of stimuli
Interventions Run-in: 2- to 3-week run-in period, during which eligible patients remained in the same
severity class (mild, moderate or severe) and had no acute exacerbations
Intervention: azithromycin, one 600 mg tablet daily for 3 days, followed by 600 mg
weekly for an additional 5 weeks
Control: matching placebo
All patients continued to receive usual care for asthma from their primary physician,
who was blinded to treatment allocation
Outcomes Symptoms, adverse events, withdrawals
Notes Funding: Pfizer
Study ID(s): NCT00245908
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk At randomisation, participants meeting fi-
nal eligibility criteria were allocated to
study medication bottles that were coded
centrally using a computerised 1:1 alloca-
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Hahn 2006 (Continued)
tion ratio blocked by site. Block size was n =
6. An independent statistician, who had no
further contact with study conduct, gener-
ated the randomisation sequences
Allocation concealment (selection bias) Low risk Study physicians, research staff, partici-
pants, and data analysts were unaware of al-
location due to central randomisation and
coding. Emergency unblinding envelopes
were available, but study sites did not re-
port opening any of them
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Blinded (patient, physician, data collector,
data analyst). Bulk studymedication tablets
were bottled, labelled and distributed by an
independent pharmaceutical service that
had no further role in study conduct
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinded (patient, physician, data collector,
data analyst)
Incomplete outcome data (attrition bias)
All outcomes
High risk We employed the ‘intention-to-treat’ prin-
ciple.We did not impute values for missing
data. Approximate 20% dropout in both
groups unaccounted for
Selective reporting (reporting bias) Low risk Prospectively registered pilot study. Speci-
fied outcomes were reported
Other bias Low risk None noted
Hahn 2012
Methods Design: parallel, randomised, placebo-controlled, double-blind trial
Duration: 12 weeks of treatment with 1 year off-treatment follow-up
Conducted in the USA. Study clinician members, staff of 5 practice-based research
networks and one community-based allergist enrolled patients from their practices for
this study
Participants Population: 75 participants were randomised to azithromycin (38) and placebo (37)
Baseline characteristics
% male: azithromycin, 29; placebo, 35
Mean age (SD): azithromycin, 45.7 (15.5); placebo, 47.4 (14.2)
% on maintenance ICS: azithromycin, 63; placebo, 81
% on maintenance LABA/ICS: azithromycin, 37; placebo, 70
Mean % predicted FEV1: not reported
Mean daily ICS dose, µg: not reported
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Chlamydophila infection: not reported
Inclusion criteria: adults 18 years of age or older with physician-diagnosed asthma
(symptomatic > 2 days per week, > 2 nights per month, in exacerbation, or a combination
of these characteristics); objective evidence for reversible airway obstruction (> 12%
and > 200 mL change in FEV1, a 25% and 60 L/min change in PEF or both) either
spontaneously or after treatment; asthma for at least 6 months before enrolment
Exclusion criteria: not English literate or has no email address or Internet access;
macrolide allergy; pregnant or lactating; 4 weeks of continuous use of macrolides, tetra-
cyclines, or quinolones within 6 months of randomisation; asthma symptoms less than 6
months’ duration; unstable asthma requiring immediate emergency care; comorbidities
likely to interfere with study assessments or follow-up (e.g. cystic fibrosis, obstructive
sleep apnoea
requiring CPAP, cardiomyopathy, congestive heart failure, terminal cancer, alcoholism
or other substance addiction, or any other serious medical condition that, in the opinion
of the study physician, would seriously interfere with or preclude assessment of study
outcomes or completion of study assessments); medical conditions for which macrolide
administration may possibly be hazardous (e.g. acute or chronic hepatitis, cirrhosis, or
other liver disease; chronic kidney disease; history of prolonged cardiac repolarisation and
QT interval or torsades de pointes); specifiedmedications for which closemonitoring has
been recommended in the setting of macrolide administration (digoxin, theophylline,
warfarin, ergotamine or dihydroergotamine, triazolam, carbamazepine, cyclosporine,
hexobarbital, or phenytoin)
Interventions Run-in: unclear
Intervention: azithromycin 600 mg, 1 tablet daily for 3 days followed by 1 tablet weekly
for 11 weeks
Control: matching placebo
Outcomes Symptoms, ACQ, changes in asthma medications, withdrawals, quality of life, exacer-
bations
Exacerbationswere recorded separately for those requiring a steroid burst, anunscheduled
or emergency visit or a hospitalisation for asthma
Notes Funding: Pfizer, Inc., donated identical matching azithromycin and placebo. The Wis-
consin Academy of Family Physicians; the American Academy of Family Physicians
Foundation, under the auspices of the Joint Grant Awards Program; the Dean Founda-
tion for Health Research and Education; and private donors provided financial support
for direct costs of AZMATICS trial
Study ID(s): NCT00266851
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk An independent statistician prepared the
randomisation codes used for subject as-
signment to the azithromycin or placebo
study arms
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Allocation concealment (selection bias) Low risk The investigators, study subjects and study
site personnel were blinded to treatment
allocation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Each study site received coded study med-
ication bottles (1:1 allocation) in blocks of
6 and was instructed to distribute them
(numbered 1 to 6) in numerical ascending
order to eligible consenting study subjects
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The investigators, study subjects, and study
site personnel were blinded to treatment
allocation
Incomplete outcome data (attrition bias)
All outcomes
High risk All analyses were by intention-to-treat, and
no
subjects with available data were excluded
from any
analysis. Withdrawal was high and quite
uneven between groups (42% and 30%)
Selective reporting (reporting bias) Low risk Prospectively registered outcomes reported
fully
Other bias Unclear risk More participants in the control groupwere
taking regular ICS or ICS/LABA combina-
tion
He 2009
Methods Design: randomised controlled trial (assumed parallel assignment; unconfirmed)
Duration: 12 weeks
Conducted in China
Participants Population: 40 participants were randomised to azithromycin (20) and placebo (20)
Baseline characteristics
% male: not reported
Mean age (SD): azithromycin, 35 (7.3); placebo, 34 (5.6)
% on maintenance ICS: not reported
% on maintenance LABA/ICS: not reported
Mean % predicted FEV1 : not reported
Mean daily ICS dose, µg: not reported
Chlamydophila infection: not reported
Inclusion criteria: We were not able to detail the specific inclusion and exclusion criteria
for this trial because it was included from an existing systematic review (Tong 2014)
. The inclusion criteria of the review required that the study be designed to evaluate
the “efficacy of prolonged treatment with macrolide antibiotics in adult patients with
asthma”
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He 2009 (Continued)
Exclusion criteria: not reported
Interventions Run-in: unknown
Intervention: azithromycin 250 mg twice weekly
Control: placebo
Outcomes FEV1, FEV1/FVC, symptoms
Notes Funding: unknown
Study ID(s): unknown
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Tong 2014 awarded 2 points for this do-
main, suggesting well reported and accept-
able methods of random sequence genera-
tion
Allocation concealment (selection bias) Unclear risk Information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Tong 2014 noted that methods of blinding
were not adequately described in the study,
although a placebo control was used
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Tong 2014 noted that methods of blinding
were not adequately described in the study
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Tong 2014 noted that withdrawals and
dropouts were not adequately described in
the study
Selective reporting (reporting bias) Unclear risk Information was not available.
Other bias Unclear risk Information was not available.
Kamada 1993
Methods Design: parallel, randomised, double-blind, placebo-controlled trial
Duration: 12 weeks
Conducted in Denver, USA
Participants Population: 19 participants were randomised to troleandomycin + methylprednisolone
(6), troleandomycin + prednisone (8), and placebo + methylprednisolone (5)
Baseline characteristics
% male: troleandomycin + methylprednisolone, 16.7; troleandomycin + prednisone,
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100; placebo + methylprednisolone, 60
Mean age (SD): troleandomycin + methylprednisolone, 14.3 (2.9); troleandomycin +
prednisone, 11.9 (2.6); placebo + methylprednisolone, 11.3 (2.7)
% on maintenance ICS: troleandomycin + methylprednisolone, 100; troleandomycin +
prednisone, 100; placebo + methylprednisolone, 100
% on maintenance LABA/ICS: not reported
Mean % predicted FEV1: not reported
Mean daily ICS dose, µg: not reported
Chlamydophila infection: not reported
Inclusion criteria: patients aged 6 to 17 meeting ATS criteria for reversible obstructive
airways disease, requiring prednisone in doses of at least 20 mg every other day, using
inhaled bronchodilators at least 4 times a day, taking theophylline with daytime peak
serum concentrations > 10 µg/mL, and having previously failed treatment with or were
receiving cromolyn sodium at the time of screening
Exclusion criteria: patients with evidence of pregnancy, smoking, viral upper respiratory
infection within 4 weeks of enrolment
Interventions Run-in: single-blind run-in period of at least 1 week
Intervention 1: troleandomycin (250 µg) + methylprednisolone once daily
Intervention 2: troleandomycin (250 µg) + prednisolone once daily
Control: placebo + methylprednisolone once daily
All patients required OCS, given as part of the randomised treatment. The mean daily
dose was 34.2 mg, 21.3 mg and 23.5 mg in intervention 1, intervention 2 and control
groups, respectively
Outcomes Symptoms score, methacholine PD20, glucocorticoid dose reduction, FEV1, PEF
Notes Funding: FDA grant FD-R 000278
Study ID(s): not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation was stratified on 2 levels of
severity of asthma. Methods unclear
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk All patients received identically appear-
ing study medications in the form of
2 blue capsules, which contained either
prednisolone or methylprednisolone, and
one white capsule, which contained either
troleandomycin or placebo, daily
Described as double-blind. Investigators
who were not blinded to data tapered doses
as tolerated by patients on the recommen-
dations of investigators who were blinded
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to data
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear who measured outcomes and
whether they were blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 2 patients dropped out of the trolean-
domycin-prednisone group, 1 of whom
could not be included in the final analy-
sis (representing 14% dropout due to small
randomisation numbers)
Selective reporting (reporting bias) High risk Several measures were only reported graph-
ically and could not be analysed
Other bias High risk Baseline characteristics were unbalanced
due to the very small numbers per group
Kapoor 2010
Methods Design: cross-over, randomised, double-blind, placebo-controlled trial
Duration: 6 weeks per treatment with 3-week washout
Conducted in India
Participants Population: 40 participants were randomised to the two treatment sequences (rox-
ithromycin-placebo and placebo-roxithromycin)
Baseline characteristics: none reported
Inclusion criteria: stable, mild-to-moderate asthma
Exclusion criteria: not described
Interventions Run-in: not described
Intervention: roxithromycin 150 mg once daily
Control: matching placebo
Outcomes Asthma control test, spirometric indices, impulse oscillometry parameters
Notes Funding: not stated
Study ID(s): not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
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Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Described as double-blind, no other details
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not described
Selective reporting (reporting bias) High risk Only abstract available, no published re-
port. Minimal details of study characteris-
tics, participants or outcomes
Other bias Unclear risk Impossible to assess
Kostadima 2004
Methods Design: parallel, randomised, double-blind, placebo-controlled trial
Duration: 8 weeks
Conducted in Greece
Participants Population: 75 participants were randomised to clarithromycin twice daily (25), 3 times
daily (25) and placebo (25)
Baseline characteristics
%male: clarithromycin twice daily, 72.7; clarithromycin 3 times daily, 40; placebo, 28.
6
Mean age (SD): clarithromycin twice daily, 48 (16); clarithromycin 3 times daily, 42
(12); placebo, 41 (16)
% on maintenance ICS: clarithromycin twice daily, 100; clarithromycin 3 times daily,
100; placebo, 100
% on maintenance LABA/ICS: not reported
Mean % predicted FEV1 (SD): clarithromycin twice daily, 85 (14); clarithromycin 3
times daily, 85 (13); placebo, 86 (14)
Mean daily ICS dose, µg: not reported
Chlamydophila infection: not reported
Inclusion criteria: Aged 18 to 70 yrs; established diagnosis of bronchial asthma for 1
year; treatment with budesonide 400 mg twice daily and salbutamol 200 mg taken as
needed less than twice weekly for at least 1 month prior to recruitment; a PD20 of < 2
mg.
Exclusion criteria: history of allergic rhinitis or occupational asthma; a history of smok-
ing (past or current); treatment with systemic corticosteroids or a history of URTI over
the 4 weeks prior to participation in the trial; FEV1 of < 50% of the predicted value or
of < 1 L at baseline; URTI or asthma exacerbation during the study period; a history
of systemic diseases (i.e. heart attack or stroke in the previous 3 months, uncontrolled
hypertension, known aortic aneurysm, epilepsy requiring drug treatment or peptic ulcer
disease); treatment with beta-blockers; and pregnancy or lactation
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Interventions Run-in: not described
Intervention 1: clarithromycin 250 mg twice daily
Intervention 2: clarithromycin 250 mg 3 times daily
Control: matching placebo dextrose
During the study, patients continued their treatment with budesonide and salbutamol.
No other medication was allowed
Outcomes Methacholine PD20
Notes Funding: not stated
Study ID(s): not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No specific details
Allocation concealment (selection bias) Unclear risk Randomised to one of the study groups by
a research nurse who played no further role
in the study
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Patients and investigators were blinded
with regard to the type of treatment re-
ceived
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear who measured outcomes
Incomplete outcome data (attrition bias)
All outcomes
High risk Patients who dropped out were not repre-
sented in the analysis; varied across groups
from 12% to 20%
Selective reporting (reporting bias) Unclear risk Several key outcomeswere not reported; re-
port does not give details of a study pro-
tocol to check that all outcomes were re-
ported
Other bias Unclear risk % male was unbalanced across groups, but
other measures were well balanced (in-
cluded age and baseline lung function)
40Macrolides for chronic asthma (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Kraft 2002
Methods Design: parallel, randomised, double-blind, placebo-controlled trial
Duration: 6 weeks
Conducted in Denver, USA
Participants Population: 55 participants were randomised to clarithromycin (26) and placebo (26);
3 withdrew due to scheduling conflicts (n = 1 participant) and non-compliance (n = 2)
Baseline characteristics: reported for the population as a whole, not for each group
% male: 49.1
Mean age (SD): 33.4 (8.9)
% on maintenance ICS: 32.7
% on maintenance LABA/ICS: 100
Mean % predicted FEV1 (SD): 69.3 (15.6)
Mean daily ICS dose, µg : not reported
Chlamydophila infection: 56.4% had evidence of C. pneumoniae or M. pneumoniae in-
fection
Inclusion criteria: Participants fulfilled criteria for asthma, exhibiting a provocative
concentration of methacholine causing a 20% decline in FEV1 of < 8 mg/mL, and
reversibility of lung function by at least 12% with bronchodilator
Exclusion criteria: inpatient status; upper or lower respiratory tract infection within
previous 3 months; use of macrolides, tetracyclines or quinolones within previous 3
months; smoking history > 5 pack-years or any cigarettes within the previous 2 years;
and significant non-asthma pulmonary disease or other medical problems
Interventions Run-in: not described
Intervention: clarithromycin 500 mg twice daily
Control: matching placebo
Outcomes Lung function, cytokine in situ production
Notes Funding: not stated
Study ID(s): not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind randomisation to treatment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind randomisation to treatment.
The individual who performed the analysis
was blinded to participants’ Mycoplasma/
Chlamydophila status, and those counting
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were blinded to treatment status
Incomplete outcome data (attrition bias)
All outcomes
Low risk 3 subjects (treatment groups unknown)
underwent analysis for Mycoplasma and
Chlamydophila but were excluded from the
treatment analysis due to scheduling diffi-
culties (n = 1) and noncompliance (n = 2)
Selective reporting (reporting bias) Unclear risk Mostly non-clinical outcomes. No prereg-
istered protocol mentioned to cross-check
Other bias Low risk None noted
Nelson 1993
Methods Design: prospective, parallel, randomised, double-blind, placebo-controlled trial
Duration: 1 to 2 years (variable)
Conducted in Denver, USA
Participants Population: 75 participants were randomised to troleandomycin + methylprednisolone
(37) and placebo + methylprednisolone (38)
Baseline characteristics
% male: troleandomycin + methylprednisolone, 36.7; placebo + methylprednisolone,
29.6
Age range: troleandomycin + methylprednisolone, 21 to 75; placebo + methylpred-
nisolone, 22 to 62
% on maintenance ICS: not reported
% on maintenance LABA/ICS: not reported
Mean % predicted FEV1: not reported
Mean daily ICS dose, µg: not reported
Chlamydophila infection: not reported
Inclusion criteria: All patients had a diagnosis of asthma with demonstrated fluctuation
in the FEV1 of 15% or more of the predicted value occurring either spontaneously or as
a result of therapy. They were required to have received a minimum of 15 mg prednisone
per day or an equivalent dose of another corticosteroid over the preceding 3 months with
a history that lower doses resulted in deterioration of asthma control and pulmonary
function. They were also required to be unable to achieve alternate-day corticosteroid
therapy, be receiving theophylline, if tolerated, with a peak serum value of greater than
10 µg/mL and inhaled b-adrenergic bronchodilator therapy at least 4 times daily
Exclusion criteria: Patients who were employing inhaled sodium cromolyn or ICS were
required to discontinue these medications before enrolment. Patients who otherwise
qualified were not enrolled if they were receiving anticonvulsant therapy, had significant
hepatic disease or were current smokers. Women of child-bearing age were required to
have a negative pregnancy test and agree to avoid pregnancy during the duration of
possible troleandomycin therapy
Interventions Run-in: Before entry, each patient’s medication was optimally adjusted and often had
received a transient increase in corticosteroid dose. Therefore, each patient’s asthma was
under good control when they were randomised, and steroids were tapered only in a way
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consistent with maintenance of continued good control
Intervention: troleandomycin 250 µg once daily + methylprednisolone
Control: matching placebo + methylprednisolone
All patients required OCS, which were given as part of the randomised treatment. Mean
daily doses were 30.8 mg and 32.0 mg for intervention and control, respectively
Outcomes Symptoms score, corticosteroid dose, blood eosinophil count, IgG, fasting blood sugar,
methacholine PD20
Notes Funding: grant from the Clinical Investigation Committee, National Jewish Centre for
Immunology and Respiratory Medicine
Study ID(s): not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised; no details
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind (presumably patients and
personnel/investigators)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear who performed the evaluations
Incomplete outcome data (attrition bias)
All outcomes
High risk Dropout higher in placebo group; data not
accounted for
Selective reporting (reporting bias) Unclear risk Most outcome data are reported; study pre-
dates requirement to register a protocol
Other bias Low risk None noted
Piacentini 2007
Methods Design: parallel, randomised, double-blind, placebo-controlled trial
Duration: 8 weeks
Conducted at the residential house of the Istituto Pio XII for asthma in Italy
Participants Population: 16 participants were randomised to azithromycin (8) and placebo (8)
Baseline characteristics
% male: azithromycin, 75; placebo, 75
Mean age (SD): azithromycin, 13.9 (2.4); placebo 12.9, (2.4)
% on maintenance ICS: azithromycin, 100; placebo, 100
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% on maintenance LABA/ICS: not reported
Mean % predicted FEV1: azithromycin, 73.5; placebo, 84.3
Mean daily ICS dose, µg: not reported
Chlamydophila infection: not reported
Inclusion criteria: children with asthma (age not specified) according to ATS criteria
Exclusion criteria: not described in detail
Interventions Run-in: not stated
Intervention: azithromycin once a day for 3 consecutive days every week, at the dosage
of 10 mg/kg body weight
Control: matching placebo
All of the patients continued their long-term treatment for asthma with a low dose of
ICS: either fluticasone, 100 to 200 µg/day, or beclomethasone dipropionate, 200 to 400
µg/day. Oral steroids were not allowed in the 3 months preceding enrolment
Outcomes Lung function, bronchial hyperresponsiveness expressed as the DRS of FEV1fall after
hypertonic saline inhalation and induced sputum
Notes Funding: not stated
Study ID(s): not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Active or placebo treatment was randomly
attributed using a computer-generated ran-
domisation code
Allocation concealment (selection bias) Unclear risk No details
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Active treatment and placebo were stored
in identical bottles, and nursing staff not
involved in any part of the study adminis-
tered the drug to the children
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Active treatment and placebo were stored
in identical bottles, and nursing staff not
involved in any part of the study adminis-
tered the drug to the children
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No mention of dropout
Selective reporting (reporting bias) Unclear risk No trial registration number reported; can-
not check if outcomes are missing
Other bias Low risk None noted
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Shoji 1999
Methods Design: cross-over, randomised, double-blind, placebo-controlled trial
Statistical analysis: Student’s paired T-test
Duration: 8 weeks per treatment with 4-week washout
Conducted at a single centre in Japan
Participants Population: 14 participants were randomised to the two treatment sequences (rox-
ithromycin-placebo and placebo-roxithromycin)
Baseline characteristics: presented for the population as a whole due to the cross-over
design
% male: 42.9
Mean age: 39.6
% on maintenance ICS: 0
% on maintenance LABA/ICS: 0
Mean % predicted FEV1: 75
Mean daily ICS dose, µg: 0
Chlamydophila infection: Not reported
Inclusion criteria: adult patients with clinical histories of aspirin-intolerant asthma.
Positive sulpyrine or lysine aspirin provocation test. Non-smokers diagnosed with mild
or moderate asthma according to ATS criteria. The patients were in a stable condition
and had been free of symptoms of respiratory infection for at least 6 weeks
Exclusion criteria: patients using oral or inhaled corticosteroids, theophylline, any anti-
leukotriene drug, such as pranlukast, or any other anti-allergic agents as well as rox-
ithromycin
Interventions Run-in: washout period of at least 4 weeks
Intervention: roxithromycin 150 mg twice daily
Control: matching placebo
Outcomes Blood eosinophils, blood neutrophils, serum ECP, sputum eosinophils, sputum neu-
trophils, sputum ECP, symptom score, FVC, FEV1, methacholine challenge
Notes Funding: grants-in-aid from Aoki International Co Ltd for Dr T Shoji
Study ID(s): not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, no details
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind (presumably patients and
personnel); matching placebo
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear who performed the assessments
and whether they were blind
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No details of dropout
Selective reporting (reporting bias) Unclear risk Outcomes were well reported. No details
of trial registration to cross-check
Other bias Low risk None noted
Simpson 2008
Methods Design: parallel, randomised, double-blind, placebo-controlled trial
Duration: 8 weeks
Participants were recruited from the Ambulatory Care Service of the Department of
Respiratory and Sleep Medicine at the John Hunter Hospital, New Lambton, Australia
Participants Population: 45 participants were randomised to clarithromycin (23) and placebo (22)
Baseline characteristics
% male: clarithromycin, 43.5; placebo, 54.5
Mean age (SD): clarithromycin, 60; placebo, 55
% on maintenance ICS: not reported
% on maintenance LABA/ICS: clarithromycin, 83; placebo, 82
Mean % predicted FEV1 (SD): clarithromycin, 73.6 (15.8); placebo, 67.6 (18.8)
Mean daily ICS dose, µg: clarithromycin, 2000; placebo, 2000
Chlamydophila infection: not reported
Inclusion criteria: non-smoking adults with symptomatic refractory asthma according
to GINA
Exclusion criteria: Participantswere excluded if they had smokedmore than5pack-years
or if they had any known sensitivity to macrolide antibiotics. Antihistamine therapies
were ceased for the duration of the study
Interventions Run-in: mentioned but not described
Intervention: clarithromycin 500 mg twice daily
Control: matching placebo
During the study, participants continued with their baseline medications as prescribed
by their physician
Outcomes Sputum IL-8 concentration, sputum neutrophil numbers and concentrations of neu-
trophil elastase and matrix metalloproteins (MMP)-9, lung function, airway hyperre-
sponsiveness to hypertonic saline, asthma control, quality of life, and symptoms
Notes Funding: not stated
Study ID(s): ACTR12605000318684
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A random-numbers table was computer
generated for treatment allocation using
permuted blocks of 4. Randomisation was
stratified according to those with high
(≥ 61%) and low neutrophil proportions
at screening. Treatment was assigned ran-
domly for each group separately to ensure
equal numbers of subjects with high neu-
trophil proportions in each of the 2 treat-
ment groups
Allocation concealment (selection bias) Unclear risk A blinded staff member, who took no fur-
ther part in the study, performed randomi-
sation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk The placebo and active medication were
packaged identically by the hospital phar-
macy department, which dispensed treat-
ments according to the random-numbers
table
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropouts reported in the study
Selective reporting (reporting bias) High risk Data reported in the paper could not be
meta-analysed (median IQR)
Other bias Unclear risk None noted
Strunk 2008
Methods Design: parallel, randomised, double-blind, placebo-controlled multicentre trial
Duration: 30 weeks, depending on asthma control
Recruited from five CARE Network centres in the USA
Participants Population: 55 patients were randomised to azithromycin (17), placebo (19), and one
other group not relevant to this review (19, Montelukast)
Baseline characteristics: presented for the population as a whole
% male: 58.2
Mean age (SD): 11.2 (2.6)
% on maintenance ICS: not reported
% on maintenance LABA/ICS: 100
Mean % predicted FEV1 (SD): 101.9 (13.7)
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Mean daily ICS dose, µg: 60% were taking 800 µg of budesonide a day at randomisation
Chlamydophila infection: nasal washes were obtained at randomisation, at week 18 and
at end of trial (either after the last planned visit or at time of treatment failure)
Inclusion criteria: Aged 6 to 17 years, and demonstration of moderate-to-severe persis-
tent asthma. Pre-bronchodilator values of FEV1 had to be ≥ 80% predicted for consid-
eration of step-down at enrolment, or ≥ 50% predicted if inadequately controlled and
step-up planned. All children demonstrated ability to perform reproducible spirometry
and had airway lability demonstrated either by an improvement in FEV1 of≥ 12% after
4 puffs of albuterol or airway hyperresponsiveness, reflected by a ≥ 20% fall in FEV1
after a methacholine dose of ≤ 12.5 mg/mL.
Exclusion criteria: very severe asthma, as indicated by more than 3 hospitalisations in
the preceding 12 months, history of intubation or mechanical ventilation within the last
year, or any history of hypoxic seizure due to asthma; history of severe sinusitis requiring
sinus surgery within the past 12 months; use of maintenance oral or systemic antibiotics
for treatment of an ongoing condition; contraindication for use of azithromycin or
montelukast; presence of lung disease other than asthma; use of digoxin, ergotamine or
dihydroergotamine, triazolam, carbamazepine, cyclosporine, hexobarbital, phenytoin,
and other macrolides
Interventions Run-in: budesonide-stable period of 6 weeks (with salmeterol 50 µg). During the run-
in, participants demonstrated evidence of inadequate control on ICS plus salmeterol,
with subsequent documentation that step-up to a higher dose of ICS (to a maximum of
1600 µg daily, again with salmeterol) established control. Participants were excluded if
they were unable to use the study drug delivery systems or to adhere to ≥ 80% of days
with use of salmeterol Diskus and oral capsules and of diary card completion during the
run-in (pre-randomisation) period
Intervention: azithromycin 250 mg (25 to 40 kg) or 500 mg (> 40 kg) once daily plus
placebo montelukast tablet
Control: 1 or 2 placebo azithromycin capsules once daily plus 1 placebo montelukast
tablet
The treatment arms were stratified according to clinical centre and dose of budesonide
(800 µg/day vs 1600 µg/day) that achieved asthma control during run-in
Participants were provided with albuterol MDI (Ventolin, GSK), prednisone (10 mg
tablets) and a written asthma action plan
Outcomes Exacerbations requiring oral corticosteroids, PEF, nocturnal awakenings, rescue medica-
tion use
Notes Funding: not stated
Study ID(s): not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation was stratified according to
clinical centre and dose of budesonide
(800 µg/day vs 1600 µg/day) that achieved
asthma control during run-in. Sequence
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generation was not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Double-masked. After the lowest dose was
achieved and control maintained for an ad-
ditional 6 weeks, the active study medica-
tion was changed to placebo (blinded to
participant). Investigators appear not to be
blind after this stage
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Double-masked, as above
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low dropout in active and placebo groups
Selective reporting (reporting bias) High risk Registration number not reported. Out-
comes could not be included in meta-anal-
ysis, and several were reported for the pop-
ulation as a whole so groups could not be
compared
Other bias Low risk None noted
Sutherland 2010
Methods Design: parallel, randomised, double-blind, placebo-controlled trial
Duration: 16 weeks
Recruited from 10 hospitals and medical centres in the USA
Participants Population: 92 patients were randomised to clarithromycin (47) and placebo (45)
Baseline characteristics:
% male: clarithromycin, 42.6; placebo, 44.4
Mean age (SD): clarithromycin, 41.3 (12.5); placebo, 37.5 (10.5)
% on maintenance ICS: not reported
% on maintenance LABA/ICS: not reported
Mean % predicted FEV1: 76.0 (whole population)
Mean daily ICS dose, µg: not reported
Chlamydophila infection: 6 clarithromycin and 6 placebo patients were PCR positive for
M. pneumoniae or C. pneumoniae
Inclusion criteria: history of physician-diagnosed asthma; methacholine PC20 less than
or equal to 16 mg/mL, FEV1 improvement greater than or equal to 12% in response
to 180 µg albuterol, or both; stable asthma for at least 6 weeks prior to study entry;
FEV1 greater than or equal to 60% of predicted result following 180 µg albuterol;
Juniper ACQ score greater than or equal to 1.5 (optimal ACQ score cut-off point for
asthma that is ’not well controlled’ by NIH/GINA guidelines); non-smoker (less than
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10 pack-per-year lifetime smoking history and no smoking in the year prior to study
entry); able to perform spirometry, as per ATS criteria; 75% adherence with diary cards,
fluticasone (monitored with Doser), and placebo pill trial (monitored electronically with
electronic Drug Exposure Monitor (eDEM) pill dose counter) for the final 2 weeks of
the 4-week run-in period; at visit 1, in steroid-naive participants, no significant adrenal
suppression, defined as a plasma cortisol concentration less than 5 µg/dL (if adrenal
suppression occurs, a 250 µg corticotropin (ACTH) stimulation test was performed.
Plasma cortisol levels were collected at baseline, and 30 and 60 minutes after the ACTH
stimulation test. Participants must have a cortisol concentration greater than 20 µg/
dL on at least one of the post-ACTH time points); absence of bronchoscopy-induced
exacerbation (if bronchoscopy-induced exacerbation has occurred, prednisone therapy
must have stopped at least 6 weeks prior to study entry); absence of respiratory tract
infection (if infection has occurred, infection-related symptoms must have stopped at
least 6 weeks prior to study entry); has experienced no more than two exacerbations or
respiratory tract infections prior to study entry; if female and able to conceive, willing to
utilise two medically acceptable forms of contraception (one non-barrier method with
single barrier method or a double barrier method)
Exclusion criteria: presence of lung disease other than asthma; presence of vocal cord
dysfunction, due to potential confounding of ACQ score; significant medical illness
other than asthma; history of atrial or ventricular tachyarrhythmia; use of anymedication
that has a significant interaction with clarithromycin, including herbal or alternative
therapies; asthma exacerbation within 6 weeks of the screening visit or during the run-
in period prior to bronchoscopy; use of systemic steroids or change in dose of controller
therapy within 6 weeks of the screening visit; inability, in the opinion of the study
investigator, to coordinate use of dry powder or metred-dose inhaler or to comply with
medication regimens; inability or unwillingness to perform required study procedures;
prolonged heart rate corrected QT interval (greater than 450 ms in women and greater
than 430 ms in men) on ECG at study entry; low potassium or magnesium levels
(based on local Asthma Clinical Research Network laboratory definitions); abnormal
elevation of liver function tests (AST, ALT, total bilirubin or alkaline phosphatase);
abnormal prothrombin time (PT) or partial thromboplastin time (PTT) results; reduced
creatinine clearance; contraindication to bronchoscopy, as determined bymedical history
or physical examination; regular consumption of grapefruit or grapefruit juice; pregnant
or breastfeeding
Interventions Run-in: 4-week run-in period, in which participants were treated with CFC-fluticasone
propionate MDI, 88 µg inhaled regularly twice daily, and inhaled CFC-albuterol sulfate,
180 µg as needed every 4 to 6 hours for relief of acute symptoms. If, at the end of the
four week run-in period, participants demonstrated an ACQ score of ≥ 1.25, they were
eligible to proceed to fibreoptic bronchoscopy for the purposes of endobronchial biopsy
for characterisation of lower airway PCR status for M. pneumoniae or C. pneumoniae.
Intervention: clarithromycin 500 mg twice daily + fluticasone propionate 88 µg twice
daily (Flovent HFA 44 µg 2 puffs twice daily)
Control: placebo + fluticasone propionate 88 µg twice daily (Flovent HFA 44 µg two
puffs twice daily)
Outcomes ACQ total score and MCID for treatment response, rescue albuterol use, morning and
evening PEF, FEV1, PC20, change in exacerbation number and frequency PC20 and
change in FeNO
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Notes Funding:Milton SHersheyMedical Center with collaboration from theNationalHeart,
Lung, and Blood Institute (NHLBI)
Study ID(s): NCT00318708
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Based on the results of PCR testing, par-
ticipants were stratified into 2 groups, ei-
ther PCR positive or PCR negative for
both M. pneumoniae and C. pneumoniae.
Within these two strata, participants were
randomly allocated in a 1:1 distribution
to the addition of either clarithromycin,
500 mg capsule by mouth twice daily, or
matched placebo
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Both participants and study personnel were
blinded to treatment allocation
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Masking: double-blind (participant, care-
giver, investigator, outcomes assessor)
Incomplete outcome data (attrition bias)
All outcomes
High risk All analyses invoked the intention-to-treat
paradigm,with truncation at the time of ex-
acerbation or treatment failure in relevant
analyses. Dropout was 17% and 11% in
clarithromycin and placebo groups, respec-
tively, and the primary outcome reported
on ClinicalTrials.gov does not appear to
have imputed for missing participants
Selective reporting (reporting bias) High risk Only group contrasts available for some
outcomes in the published paper, and only
the primary outcome and adverse events
have been uploaded to ClinicalTrials.gov
Other bias Low risk None noted
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Wang 2012
Methods Design: randomised controlled trial (assumed parallel assignment; unconfirmed)
Duration: 8 weeks
Conducted in China
Participants Population: 45 patients were randomised to clarithromycin (23) and placebo (22)
Baseline characteristics:
% male: not reported
Mean age: not reported
% on maintenance ICS: not reported
% on maintenance LABA/ICS: not reported
Mean % predicted FEV1: not reported
Mean daily ICS dose, µg: not reported
Chlamydophila infection: not reported
Inclusion criteria: We were not able to detail the specific inclusion and exclusion criteria
for this trial because it was included from an existing systematic review (Tong 2014)
. The inclusion criteria of the review required that the study be designed to evaluate
the “efficacy of prolonged treatment with macrolide antibiotics in adult patients with
asthma”
Exclusion criteria: not reported
Interventions Run-in: unknown
Intervention: clarithromycin 500 mg twice daily
Control: placebo
Outcomes Trough FEV1, cell counts, symptoms
Notes Funding: unknown
Study ID(s): unknown
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Tong 2014 awarded 2 points for this do-
main, suggesting well reported and accept-
able methods of random sequence genera-
tion
Allocation concealment (selection bias) Unclear risk Information was not available
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Tong 2014 noted that methods of blinding
were reported but not in detail. A placebo
control was used
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Tong 2014 noted that methods of blinding
were not adequately described in the study
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Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Tong 2014 noted that withdrawals and
dropouts were not adequately described in
the study
Selective reporting (reporting bias) Unclear risk Information was not available.
Other bias Unclear risk Information was not available.
Wang 2014
Methods Design: randomised controlled trial (assumed parallel assignment; unconfirmed)
Duration: 52 weeks
Conducted in China
Participants Population: 58 patients were randomised to azithromycin (29) and placebo (29)
Baseline characteristics:
% male: not reported
Mean age (SD): azithromycin, 28.4 (16.0); placebo 29.6 (14.2)
% on maintenance ICS: not reported
% on maintenance LABA/ICS: not reported
Mean % predicted FEV1 (SD): not reported
Mean daily ICS dose, µg (SD): not reported
Chlamydophila infection: not reported
Inclusion criteria: We were not able to detail the specific inclusion and exclusion criteria
for this trial because it was included from an existing systematic review (Tong 2014)
. The inclusion criteria of the review required that the study be designed to evaluate
the “efficacy of prolonged treatment with macrolide antibiotics in adult patients with
asthma”
Exclusion criteria: not reported
Interventions Run-in: unknown
Intervention: azithromycin 250 mg twice weekly
Control: placebo
Outcomes FEV1, PEF
Notes Funding: unknown
Study ID(s): unknown
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Tong 2014 awarded 2 points for this do-
main, suggesting well reported and accept-
able methods of random sequence genera-
tion
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Allocation concealment (selection bias) Unclear risk Information was not available
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Tong 2014 noted that methods of blinding
were not adequately described in the study,
although a placebo control was used
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Tong 2014 noted that methods of blinding
were not adequately described in the study
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Tong 2014 noted that withdrawals and
dropouts were not adequately described in
the study
Selective reporting (reporting bias) Unclear risk Information was not available.
Other bias Unclear risk Information was not available.
Xiao 2013
Methods Design: randomised controlled trial (assumed parallel assignment - unconfirmed)
Duration: 12 weeks
Conducted in China
Participants Population: 210 patients were randomised to roxithromycin (106) and placebo (104)
Baseline characteristics:
% male: Not reported
Mean age (SD): roxithromycin, 34.5 (7.2); placebo, 33.7 (8.3)
% on maintenance ICS: not reported
% on maintenance LABA/ICS: not reported
Mean % predicted FEV1: not reported
Mean daily ICS dose, µg: not reported
Chlamydophila infection: not reported
Inclusion criteria: We were not able to detail the specific inclusion and exclusion criteria
for this trial because it was included from an existing systematic review (Tong 2014)
. The inclusion criteria of the review required that the study be designed to evaluate
the “efficacy of prolonged treatment with macrolide antibiotics in adult patients with
asthma”
Exclusion criteria: Not reported
Interventions Run-in: unknown
Intervention: roxithromycin 150 mg twice daily
Control: placebo
Outcomes FEV1, FVC, PEF
Notes Funding: unknown
Study ID(s): unknown
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Xiao 2013 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Tong 2014 awarded 2 points for this do-
main, suggesting well reported and accept-
able methods of random sequence genera-
tion
Allocation concealment (selection bias) Unclear risk Information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Tong 2014 noted that methods of blinding
were not adequately described in the study,
although a placebo control was used
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Tong 2014 noted that methods of blinding
were not adequately described in the study
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Information was not available.
Selective reporting (reporting bias) Unclear risk Information was not available.
Other bias Unclear risk Information was not available.
Yan 2008
Methods Design: randomised controlled trial (assumed parallel assignment; unconfirmed)
Duration: 4 weeks
Conducted in China
Participants Population: 40 patients were randomised to roxithromycin (20) and placebo (20)
Baseline characteristics:
% male: not reported
Mean age: not reported
% on maintenance ICS: not reported
% on maintenance LABA/ICS: not reported
Mean % predicted FEV1: not reported
Mean daily ICS dose, µg: not reported
Chlamydophila infection: not reported
Inclusion criteria: We were not able to detail the specific inclusion and exclusion criteria
for this trial because it was included from an existing systematic review (Tong 2014)
. The inclusion criteria of the review required that the study be designed to evaluate
the “efficacy of prolonged treatment with macrolide antibiotics in adult patients with
asthma”
Exclusion criteria: not reported
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Yan 2008 (Continued)
Interventions Run-in: unknown
Intervention: roxithromycin 150 mg twice daily
Control: placebo
Outcomes Trough FEV1, FEV1, PEF, cell counts, symptoms
Notes Funding: unknown
Study ID(s): unknown
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Tong 2014 awarded 2 points for this do-
main suggesting well reported and accept-
able methods of random sequence genera-
tion
Allocation concealment (selection bias) Unclear risk Information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Tong 2014 noted that methods of blinding
were not adequately described in the study,
although a placebo control was used
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Tong 2014 noted that methods of blinding
were not adequately described in the study
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Tong 2014 noted that there was a detailed
report of withdrawals and dropouts in the
study, but we were unable to assess the level
of dropout and how this might have af-
fected the results
Selective reporting (reporting bias) Unclear risk Information was not available.
Other bias Unclear risk Information was not available.
Zhang 2013
Methods Design: randomised controlled trial (assumed parallel assignment; unconfirmed)
Duration: 60 days (8.7 weeks)
Conducted in China
Participants Population: 60 patients were randomised to azithromycin (30) and placebo (30)
Baseline characteristics:
% male: not reported
Mean age: not reported
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Zhang 2013 (Continued)
% on maintenance ICS: not reported
% on maintenance LABA/ICS: not reported
Mean % predicted FEV1: not reported
Mean daily ICS dose, µg: not reported
Chlamydophila infection: not reported
Inclusion criteria: We were not able to detail the specific inclusion and exclusion criteria
for this trial because it was included from an existing systematic review (Tong 2014)
. The inclusion criteria of the review required that the study be designed to evaluate
the “efficacy of prolonged treatment with macrolide antibiotics in adult patients with
asthma”
Exclusion criteria: not reported
Interventions Run-in: unknown
Intervention: azithromycin 100 mg once daily
Control: placebo
Outcomes Trough FEV1
Notes Funding: unknown
Study ID(s): unknown
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Tong 2014 awarded 2 points for this do-
main, suggesting well reported and accept-
able methods of random sequence genera-
tion
Allocation concealment (selection bias) Unclear risk Information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Tong 2014 noted that methods of blinding
were not adequately described in the study,
although a placebo control was used
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Tong 2014 noted that methods of blinding
were not adequately described in the study
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Tong 2014 noted that withdrawals and
dropouts were not adequately described in
the study
Selective reporting (reporting bias) Unclear risk Information was not available.
Other bias Unclear risk Information was not available.
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ACQ: Asthma Control Questionnaire; ACT: Asthma Control Test; ACTH; adrenocorticotropic hormone; ALT: alanine aminotrans-
ferase;AQLQ: AsthmaQuality of LifeQuestionnaire;AST: aspartate aminotransferase;ATS: AmericanThoracic Society;CFC: chloro
fluorocarbon; CPAP: continuous positive airway pressure; DRS: dose-response slope; ECG: electrocardiography;ECP: eosinophil
cationic protein; FDA: Food and Drug Administration (USA); FeNO: fractional exhaled nitric oxide; FEV1 : forced expiratory vol-
ume in one second; FVC: forced vital capacity; GINA: Global Initiative for Asthma;ICS: inhaled corticosteroids;IgA: immunoglob-
ulin A; IgE: immunoglobulin E; IgG: immunoglobulin G; IL-8: interleukin 8; IQR: interquartile range; ITT: intention-to-treat;
LABA: long-acting beta2-agonist; LCQ: Leicester Cough Questionnaire; LRTI: lower respiratory tract infection; NIH: National
Institutes of Health (USA)MCID: minimal clinically important difference;MDI: metred dose inhaler;MPN: methylprednisolone;
OCS: oral corticosteroids; PC20 or PD20 : provocative concentration (or dose) causing a 20% fall in forced expiratory volume in 1
second (FEV1); Log PC20 : logarithm to the base 10 of PC20; PCR: polymerase chain reaction; PEF: peak expiratory flow; PBRN:
practice-based research network; QT interval: measure of the time between the start of the Q wave and the end of the T wave in
the heart’s electrical cycle; SD: standard deviation; ULN: upper limit normal; URTI: upper respiratory tract infections.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Andrade 1983 Study period too short (6 days) and randomisation method not adequate
Anon 2009 Commentary. Not an RCT
Ball 1990 Study period too short (2 weeks)
Cogo 1994 Study of inadequate duration
Ebling 1984 Basic science study
Feldman 1997 Basic science in vitro study
Gotfried 2004 The study was suspended because the slow enrolment of patients. The clarithromycin and placebo groups were
unequal in size, and the final analysis was performed only within the treatment group, analysing data before and
after the macrolide therapy within the same patients. Therefore the study was excluded because there were no
between-study comparisons
Hueston 1991 Patients not affected by asthma
Itkin 1970 Short (2 weeks) duration
Kaplan 1958 Not an RCT
Koh 1997 Patients are children with bronchiectasis; 7 children had asthma and insufficient data were reported for these
children separately
Koutsoubari 2012 Acute exacerbations in children, trial less than 4 weeks
Spector 1974 Not an RCT
Szefler 1980 Not an RCT
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(Continued)
Szefler 1982a Not an RCT
Szefler 1982b Not an RCT
Takamura 2001 Not an RCT
Wald 1986 Not an RCT
Weinberger 1977 Not an RCT
Zeiger 1980 Not an RCT
RCT: randomised controlled trial.
Characteristics of studies awaiting assessment [ordered by study ID]
ACTRN12609000197235
Methods Large-scale, parallel, multicentre, double-blind, placebo-controlled randomised trial
Participants Patients with symptomatic stable asthma with ACQ > 0.75, confirmed variable airflow obstruction, maintenance
combination therapy. Minimum age 18 years, males and females. Target sample size 420
Interventions Azithromycin 500 mg (2 x 250 mg tablets to be administered by the oral route) 3 times weekly for 48 weeks
Placebo 3 times weekly for 48 weeks
Outcomes Asthma exacerbations, Juniper AsthmaQuality of Life Questionnaire, safety, Juniper Asthma Control Questionnaire,
Symptom diary data
Notes Recruitment status: recruiting
Government funded in Australia
Trial ID: ACTRN12609000197235
ACQ: Asthma Control Questionnaire.
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D A T A A N D A N A L Y S E S
Comparison 1. Macrolide versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Exacerbation requiring
hospitalisation
2 143 Odds Ratio (M-H, Fixed, 95% CI) 0.98 [0.13, 7.23]
2 ’Severe’ exacerbation - requiring
at least OCS
5 290 Odds Ratio (M-H, Fixed, 95% CI) 0.82 [0.43, 1.57]
3 Symptom scales 4 156 Std. Mean Difference (Fixed, 95% CI) -0.35 [-0.67, -0.02]
4 Asthma Control 4 353 Std. Mean Difference (Fixed, 95% CI) -0.05 [-0.26, 0.15]
5 Asthma Quality of Life
Questionnaire (AQLQ)
5 389 Mean Difference (Fixed, 95% CI) 0.06 [-0.12, 0.24]
6 Rescue medication puffs/day 4 314 Mean Difference (Fixed, 95% CI) -0.26 [-0.65, 0.12]
7 Morning PEF (L/min) 4 289 Mean Difference (Fixed, 95% CI) 2.22 [-9.73, 14.17]
8 Evening PEF (L/min) 3 212 Mean Difference (Fixed, 95% CI) 1.97 [-12.68, 16.62]
9 FEV1 (L) 9 631 Mean Difference (Fixed, 95% CI) 0.08 [0.02, 0.14]
10 Bronchial hyperresponsiveness
(BHR)
Other data No numeric data
11 Oral corticosteroid dose 2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
12 Serious adverse events (incl
mortality)
7 434 Odds Ratio (M-H, Fixed, 95% CI) 0.80 [0.24, 2.68]
13 Withdrawal 9 563 Odds Ratio (M-H, Fixed, 95% CI) 0.95 [0.59, 1.52]
14 Blood eosinophils 2 Mean Difference (Fixed, 95% CI) -33.50 [-36.11, -30.
90]
15 Sputum eosinophils 3 Mean Difference (Fixed, 95% CI) Totals not selected
16 ECP in serum 2 Mean Difference (Fixed, 95% CI) -12.84 [-15.67, -10.
00]
17 ECP in sputum 2 Mean Difference (Fixed, 95% CI) -1.45 [-1.78, -1.11]
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Analysis 1.1. Comparison 1 Macrolide versus placebo, Outcome 1 Exacerbation requiring hospitalisation.
Review: Macrolides for chronic asthma
Comparison: 1 Macrolide versus placebo
Outcome: 1 Exacerbation requiring hospitalisation
Study or subgroup Macrolide Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Amayasu 2000 (1) 0/17 0/17 Not estimable
Brusselle 2013 2/55 2/54 100.0 % 0.98 [ 0.13, 7.23 ]
Total (95% CI) 72 71 100.0 % 0.98 [ 0.13, 7.23 ]
Total events: 2 (Macrolide), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.02 (P = 0.99)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours macrolide Favours placebo
(1) Crossover trial - no events occurred in either phase. Participants have not been split to avoid double counting as the study does not contribute to the effect estimate.
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Analysis 1.2. Comparison 1 Macrolide versus placebo, Outcome 2 ’Severe’ exacerbation - requiring at least
OCS.
Review: Macrolides for chronic asthma
Comparison: 1 Macrolide versus placebo
Outcome: 2 ’Severe’ exacerbation - requiring at least OCS
Study or subgroup Macrolide Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Amayasu 2000 (1) 0/17 0/17 Not estimable
Brusselle 2013 (2) 26/55 26/54 68.6 % 0.97 [ 0.46, 2.05 ]
Hahn 2006 0/19 0/17 Not estimable
Kostadima 2004 (3) 4/50 3/25 18.2 % 0.64 [ 0.13, 3.10 ]
Strunk 2008 (4) 1/17 3/19 13.2 % 0.33 [ 0.03, 3.55 ]
Total (95% CI) 158 132 100.0 % 0.82 [ 0.43, 1.57 ]
Total events: 31 (Macrolide), 32 (Placebo)
Heterogeneity: Chi2 = 0.83, df = 2 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 0.59 (P = 0.55)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours macrolide Favours placebo
(1) Crossover trial - no events occurred in either phase. Participants have not been split to avoid double counting as the study does not contribute to the effect estimate.
(2) Defined as those requiring hospitalisation/ER visit/systemic corticosteroids/LRTI requiring antibiotics
(3) Two dose groups merged. Exacerbation not defined.
(4) Exacerbation defined as requiring oral steroids
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Analysis 1.3. Comparison 1 Macrolide versus placebo, Outcome 3 Symptom scales.
Review: Macrolides for chronic asthma
Comparison: 1 Macrolide versus placebo
Outcome: 3 Symptom scales
Study or subgroup Macrolide Placebo
Std. Mean
Difference
(SE)
Std.
Mean
Difference Weight
Std.
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
Amayasu 2000 (1) 17 17 -1.26 (0.377) 19.2 % -1.26 [ -2.00, -0.52 ]
Hahn 2006 19 17 -0.8307 (0.3496) 22.3 % -0.83 [ -1.52, -0.15 ]
Hahn 2012 (2) 38 37 0.1734 (0.2314) 51.0 % 0.17 [ -0.28, 0.63 ]
Kamada 1993 6 5 -0.097 (0.6061) 7.4 % -0.10 [ -1.28, 1.09 ]
Total (95% CI) 80 76 100.0 % -0.35 [ -0.67, -0.02 ]
Heterogeneity: Chi2 = 13.01, df = 3 (P = 0.005); I2 =77%
Test for overall effect: Z = 2.10 (P = 0.036)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours macrolide Favours placebo
(1) 4-point scale. This is a crossover study including 17 participants who received macrolide and placebo in a random order.
(2) 0-4 scale (lower is better)
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Analysis 1.4. Comparison 1 Macrolide versus placebo, Outcome 4 Asthma Control.
Review: Macrolides for chronic asthma
Comparison: 1 Macrolide versus placebo
Outcome: 4 Asthma Control
Study or subgroup Macrolide Placebo
Std. Mean
Difference
(SE)
Std.
Mean
Difference Weight
Std.
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
Brusselle 2013 (1) 55 54 -0.12 (0.1633) 40.9 % -0.12 [ -0.44, 0.20 ]
Cameron 2012 (2) 39 38 0.1877 (0.2285) 20.9 % 0.19 [ -0.26, 0.64 ]
Hahn 2012 (3) 38 37 0.0109 (0.231) 20.4 % 0.01 [ -0.44, 0.46 ]
Sutherland 2010 47 45 -0.24 (0.2476) 17.8 % -0.24 [ -0.73, 0.25 ]
Total (95% CI) 179 174 100.0 % -0.05 [ -0.26, 0.15 ]
Heterogeneity: Chi2 = 1.92, df = 3 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 0.48 (P = 0.63)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours macrolide Favours placebo
(1) ACQ adjusted mean difference as change from baseline
(2) ACQ
(3) ACQ
64Macrolides for chronic asthma (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.5. Comparison 1 Macrolide versus placebo, Outcome 5 Asthma Quality of Life Questionnaire
(AQLQ).
Review: Macrolides for chronic asthma
Comparison: 1 Macrolide versus placebo
Outcome: 5 Asthma Quality of Life Questionnaire (AQLQ)
Study or subgroup Macrolide Placebo Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
Brusselle 2013 (1) 55 54 0.12 (0.1633) 31.9 % 0.12 [ -0.20, 0.44 ]
Cameron 2012 39 38 -0.31 (0.1939) 22.6 % -0.31 [ -0.69, 0.07 ]
Hahn 2006 19 17 0.25 (0.3042) 9.2 % 0.25 [ -0.35, 0.85 ]
Hahn 2012 38 37 0.17 (0.2371) 15.1 % 0.17 [ -0.29, 0.63 ]
Sutherland 2010 47 45 0.2 (0.2) 21.2 % 0.20 [ -0.19, 0.59 ]
Total (95% CI) 198 191 100.0 % 0.06 [ -0.12, 0.24 ]
Heterogeneity: Chi2 = 4.87, df = 4 (P = 0.30); I2 =18%
Test for overall effect: Z = 0.64 (P = 0.52)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours placebo Favours macrolide
(1) Mean change from baseline
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Analysis 1.6. Comparison 1 Macrolide versus placebo, Outcome 6 Rescue medication puffs/day.
Review: Macrolides for chronic asthma
Comparison: 1 Macrolide versus placebo
Outcome: 6 Rescue medication puffs/day
Study or subgroup Macrolide Placebo Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
Brusselle 2013 55 54 -0.16 (0.3674) 28.4 % -0.16 [ -0.88, 0.56 ]
Cameron 2012 39 38 -0.3 (0.5102) 14.7 % -0.30 [ -1.30, 0.70 ]
Hahn 2006 19 17 0.59 (0.5196) 14.2 % 0.59 [ -0.43, 1.61 ]
Sutherland 2010 47 45 -0.6 (0.3) 42.6 % -0.60 [ -1.19, -0.01 ]
Total (95% CI) 160 154 100.0 % -0.26 [ -0.65, 0.12 ]
Heterogeneity: Chi2 = 4.04, df = 3 (P = 0.26); I2 =26%
Test for overall effect: Z = 1.34 (P = 0.18)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours macrolide Favours placebo
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Analysis 1.7. Comparison 1 Macrolide versus placebo, Outcome 7 Morning PEF (L/min).
Review: Macrolides for chronic asthma
Comparison: 1 Macrolide versus placebo
Outcome: 7 Morning PEF (L/min)
Study or subgroup Macrolide Placebo Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
Brusselle 2013 55 54 3.96 (9.8777) 38.1 % 3.96 [ -15.40, 23.32 ]
Cameron 2012 39 38 -10.3 (18.7759) 10.5 % -10.30 [ -47.10, 26.50 ]
Kamada 1993 (1) 6 5 52.1 (57.1487) 1.1 % 52.10 [ -59.91, 164.11 ]
Sutherland 2010 47 45 2.4 (8.6) 50.2 % 2.40 [ -14.46, 19.26 ]
Total (95% CI) 147 142 100.0 % 2.22 [ -9.73, 14.17 ]
Heterogeneity: Chi2 = 1.24, df = 3 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 0.36 (P = 0.72)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours placebo Favours macrolide
(1) PEF pre-dose
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Analysis 1.8. Comparison 1 Macrolide versus placebo, Outcome 8 Evening PEF (L/min).
Review: Macrolides for chronic asthma
Comparison: 1 Macrolide versus placebo
Outcome: 8 Evening PEF (L/min)
Study or subgroup Macrolide Placebo Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
Brusselle 2013 55 54 3.84 (13.7452) 29.6 % 3.84 [ -23.10, 30.78 ]
Kamada 1993 (1) 6 5 19.1 (61.2888) 1.5 % 19.10 [ -101.02, 139.22 ]
Sutherland 2010 47 45 0.8 (9) 69.0 % 0.80 [ -16.84, 18.44 ]
Total (95% CI) 108 104 100.0 % 1.97 [ -12.68, 16.62 ]
Heterogeneity: Chi2 = 0.11, df = 2 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 0.26 (P = 0.79)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours placebo Favours macrolide
(1) PEF post-dose
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Analysis 1.9. Comparison 1 Macrolide versus placebo, Outcome 9 FEV1 (L).
Review: Macrolides for chronic asthma
Comparison: 1 Macrolide versus placebo
Outcome: 9 FEV1 (L)
Study or subgroup Macrolide Placebo Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Fixed,95% CI IV,Fixed,95% CI
Amayasu 2000 (1) 17 17 -0.01 (0.9) 0.1 % -0.01 [ -1.77, 1.75 ]
Cameron 2012 39 38 0.03 (0.0561) 28.7 % 0.03 [ -0.08, 0.14 ]
He 2009 20 20 0.09 (0.0459) 42.9 % 0.09 [ 0.00, 0.18 ]
Kraft 2002 26 26 -0.05 (0.2126) 2.0 % -0.05 [ -0.47, 0.37 ]
Shoji 1999 (2) 14 14 0.12 (0.3137) 0.9 % 0.12 [ -0.49, 0.73 ]
Sutherland 2010 (3) 47 45 0 (0.1) 9.0 % 0.0 [ -0.20, 0.20 ]
Wang 2014 29 29 0.15 (0.1225) 6.0 % 0.15 [ -0.09, 0.39 ]
Xiao 2013 106 104 0.15 (0.1071) 7.9 % 0.15 [ -0.06, 0.36 ]
Yan 2008 20 20 0.4 (0.1939) 2.4 % 0.40 [ 0.02, 0.78 ]
Total (95% CI) 318 313 100.0 % 0.08 [ 0.02, 0.14 ]
Heterogeneity: Chi2 = 5.35, df = 8 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 2.59 (P = 0.0097)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours placebo Favours macrolide
(1) This is a crossover study including 17 participants who received macrolide and placebo in a random order.
(2) Crossover study with 14 participants who received both treatments.
(3) Pre-bronchodilator
Analysis 1.10. Comparison 1 Macrolide versus placebo, Outcome 10 Bronchial hyperresponsiveness (BHR).
Bronchial hyperresponsiveness (BHR)
Study Measure of BHR (units) Results Conclusions
Amayasu 2000 Methacoline challenge test (log
PC20)
Clarithromycin: 2.96 ± 0.57
Placebo: 2.60 ± 0.51 (P < 0.01)
Clarithromycin significantly re-
duced BHR in patients with allergic
intermittent asthma
Cameron 2012 Methacoline challenge test (log
PC20)
Azithromycin: 0.20 ± 1.52
Placebo: 0.19 ± 1.29 (P < 0.93)
No effect of azithromycin in smok-
ers with persistent asthma
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Bronchial hyperresponsiveness (BHR) (Continued)
Kamada 1993 Methacoline challenge test (PC20) 16 of the 19 patients took test at
the beginning and at the end of the
analysis. Data are reported graphi-
cally and not included in the main
analysis
No significant difference at the
end of the treatment was recorded
among the 3 arms of the study
Kostadima 2004 Methacoline challenge test (PC20) Median interquartile range (IQR)
before and after the treatment:
Clarithromycin 250 mg twice daily:
0.3 mg (0.1 to 1) and 1.3 mg (0.6 to
2) mg (P < 0.001)
Clarithromycin 250 mg 3 times-
daily: 0.4 mg (0.1 to 0.9) mg (P < 0.
001)
Placebo: 0.4 mg (0.1 to 0.9) and 0.
3 mg (0.1 to 0.6) mg (P not signifi-
cant)
Compared to the baseline, there was
a significant increase in the median
PC20 in the 2 macrolide groups but
not in the placebo group
Nelson 1993 Methacoline challenge test (PC20) 11 out of 27 placebo group patients
and 13 out of 30 troleandomycin
group patients took the test at the
start and end of the study.
Troleandomycin: +1.89 mg/mL
Placebo: +0.55 mg/mL
No significant effect of trolean-
domycin was recorded in compar-
isons within and between the study
groups
Piacentini 2007 Hypertonic saline challenge (dose-
response slope)
Azithromycin: 2.75 ± 2.12 to 1.42 ±
1.54 (P < 0.02)
Placebo: 1.48 ± 1.75 to 1.01 ± 1.38
(P = 0.21)
The reduction of BHR in the treat-
ment group was driven by the
change from the baseline in 3 out
of 9 patients. No significant differ-
ence was observed in a comparison
between the groups. Study in chil-
dren
Shoji 1999 Sulpyrine inhalation testing (log
PC20-sulpyrine)
Roxitrhromycin: 1.18 ± 0.40
Placebo: 1.15 ± 0.43
No significant improvement of
BHR was recorded within and be-
tween group comparisons
Simpson 2008 Hypertonic saline challenge (dose-
response slope; DSR)
DSR before: 1.8 (0.6 to 6.4) and af-
ter clarithromycin: 1 (0.5 to 4.2)
DSR before: 1 (0.6 to 3.2) and after
placebo: 1 (0.5 to 3.3)
No significant improvement of
BHR was recorded within and be-
tween group comparisons
Sutherland 2010 Methacoline challenge test (PC20
doubling dose)
Analysis stratified for (polymerase
chain reaction) PCR positivity for
M. pneumoniae or C. pneumonia.
Difference between clarithromycin
and placebo groups:
Irrespective of PCR status: + 1.2 ±
0.5, P = 0.01;
In patients with positive PCR status:
+ 0.9 ± 1.8, P = 0.6;
BHR was significantly improved by
clarithromycin compared to placebo
in the whole population and in
the PCR negative groups, but not
among the PCR positive patients
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Bronchial hyperresponsiveness (BHR) (Continued)
In patients with negative PCR sta-
tus: + 1.2 ± 0.5, P = 0.02.
Analysis 1.11. Comparison 1 Macrolide versus placebo, Outcome 11 Oral corticosteroid dose.
Review: Macrolides for chronic asthma
Comparison: 1 Macrolide versus placebo
Outcome: 11 Oral corticosteroid dose
Study or subgroup Macrolide Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Kamada 1993 (1) 6 4.9 (2.45) 5 11.5 (5.5902) -6.60 [ -11.88, -1.32 ]
Nelson 1993 (2) 29 6.3 (7.0007) 27 10.4 (6.755) -4.10 [ -7.70, -0.50 ]
-20 -10 0 10 20
Favours macrolide Favours placebo
(1) Lowest tolerated mg/day in prednisolone equivalent during the 12 week study
(2) Lowest stable dose (mg/day of methylprednisolone) achieved between study entry and 12 month follow-up
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Analysis 1.12. Comparison 1 Macrolide versus placebo, Outcome 12 Serious adverse events (incl mortality).
Review: Macrolides for chronic asthma
Comparison: 1 Macrolide versus placebo
Outcome: 12 Serious adverse events (incl mortality)
Study or subgroup Macrolide Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Amayasu 2000 (1) 0/17 0/17 Not estimable
Brusselle 2013 4/55 3/54 48.0 % 1.33 [ 0.28, 6.26 ]
Cameron 2012 0/39 0/38 Not estimable
Hahn 2006 0/19 1/17 26.3 % 0.28 [ 0.01, 7.40 ]
Hahn 2012 0/38 1/37 25.7 % 0.32 [ 0.01, 8.01 ]
Kamada 1993 0/6 0/5 Not estimable
Sutherland 2010 0/47 0/45 Not estimable
Total (95% CI) 221 213 100.0 % 0.80 [ 0.24, 2.68 ]
Total events: 4 (Macrolide), 5 (Placebo)
Heterogeneity: Chi2 = 1.13, df = 2 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 0.37 (P = 0.71)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours macrolide Favours placebo
(1) Crossover trial - no events occurred in either phase. Participants have not been split to avoid double counting as the study does not contribute to the effect estimate.
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Analysis 1.13. Comparison 1 Macrolide versus placebo, Outcome 13 Withdrawal.
Review: Macrolides for chronic asthma
Comparison: 1 Macrolide versus placebo
Outcome: 13 Withdrawal
Study or subgroup Macrolide Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Brusselle 2013 2/55 5/54 13.9 % 0.37 [ 0.07, 1.99 ]
Hahn 2006 5/24 4/21 9.7 % 1.12 [ 0.26, 4.86 ]
Hahn 2012 16/38 11/37 18.5 % 1.72 [ 0.66, 4.47 ]
Kamada 1993 0/6 0/5 Not estimable
Kostadima 2004 (1) 8/50 4/25 12.8 % 1.00 [ 0.27, 3.70 ]
Nelson 1993 7/37 11/38 25.2 % 0.57 [ 0.19, 1.69 ]
Simpson 2008 0/23 1/22 4.3 % 0.30 [ 0.01, 7.89 ]
Strunk 2008 2/17 1/19 2.4 % 2.40 [ 0.20, 29.13 ]
Sutherland 2010 5/47 5/45 13.1 % 0.95 [ 0.26, 3.54 ]
Total (95% CI) 297 266 100.0 % 0.95 [ 0.59, 1.52 ]
Total events: 45 (Macrolide), 42 (Placebo)
Heterogeneity: Chi2 = 4.58, df = 7 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 0.23 (P = 0.82)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours macrolide Favours placebo
(1) Two dose groups merged
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Analysis 1.14. Comparison 1 Macrolide versus placebo, Outcome 14 Blood eosinophils.
Review: Macrolides for chronic asthma
Comparison: 1 Macrolide versus placebo
Outcome: 14 Blood eosinophils
Study or subgroup Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
Amayasu 2000 (1) -35.5 (1.704) 60.8 % -35.50 [ -38.84, -32.16 ]
Shoji 1999 -30.4 (2.1225) 39.2 % -30.40 [ -34.56, -26.24 ]
Total (95% CI) 100.0 % -33.50 [ -36.11, -30.90 ]
Heterogeneity: Chi2 = 3.51, df = 1 (P = 0.06); I2 =72%
Test for overall effect: Z = 25.21 (P < 0.00001)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
Favours macrolide Favours placebo
(1) Amayasu 2000 and Shoji 1999 are both crossover studies including 17 and 14 participants respectively who received macrolide and placebo in a random order.
Analysis 1.15. Comparison 1 Macrolide versus placebo, Outcome 15 Sputum eosinophils.
Review: Macrolides for chronic asthma
Comparison: 1 Macrolide versus placebo
Outcome: 15 Sputum eosinophils
Study or subgroup Mean Difference (SE)
Mean
Difference
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
Amayasu 2000 (1) -77 (8.852) -77.00 [ -94.35, -59.65 ]
Cameron 2012 3.5 (3.9479) 3.50 [ -4.24, 11.24 ]
Shoji 1999 -80 (8.9642) -80.00 [ -97.57, -62.43 ]
-100 -50 0 50 100
Favours macrolide Favours placebo
(1) Amayasu 2000 and Shoji 1999 are both crossover studies including 17 and 14 participants respectively who received macrolide and placebo in a random order.
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Analysis 1.16. Comparison 1 Macrolide versus placebo, Outcome 16 ECP in serum.
Review: Macrolides for chronic asthma
Comparison: 1 Macrolide versus placebo
Outcome: 16 ECP in serum
Study or subgroup Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
Amayasu 2000 (1) -14.4 (2.021) 51.2 % -14.40 [ -18.36, -10.44 ]
Shoji 1999 -11.2 (2.07) 48.8 % -11.20 [ -15.26, -7.14 ]
Total (95% CI) 100.0 % -12.84 [ -15.67, -10.00 ]
Heterogeneity: Chi2 = 1.22, df = 1 (P = 0.27); I2 =18%
Test for overall effect: Z = 8.88 (P < 0.00001)
Test for subgroup differences: Not applicable
-20 -10 0 10 20
Favours macrolide Favours placebo
(1) Amayasu 2000 and Shoji 1999 are both crossover studies including 17 and 14 participants respectively who received macrolide and placebo in a random order.
Analysis 1.17. Comparison 1 Macrolide versus placebo, Outcome 17 ECP in sputum.
Review: Macrolides for chronic asthma
Comparison: 1 Macrolide versus placebo
Outcome: 17 ECP in sputum
Study or subgroup Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
IV,Fixed,95% CI IV,Fixed,95% CI
Amayasu 2000 (1) -1.6 (0.2448) 48.9 % -1.60 [ -2.08, -1.12 ]
Shoji 1999 -1.3 (0.2397) 51.1 % -1.30 [ -1.77, -0.83 ]
Total (95% CI) 100.0 % -1.45 [ -1.78, -1.11 ]
Heterogeneity: Chi2 = 0.77, df = 1 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 8.45 (P < 0.00001)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
Favours macrolide Favours placebo
(1) Amayasu 2000 and Shoji 1999 are both crossover studies including 17 and 14 participants respectively who received macrolide and placebo in a random order.
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A D D I T I O N A L T A B L E S
Table 1. Summary characteristics of included studies at baseline
Study ID Country Num-
ber of par-
ticipants
Design Duration
(weeks)
Macrolide
dose and
schedule
Mean age % male % on ICS % Predicted
FEV1
Amayasu
2000
Japan and
USA
17 C, R, DB,
PC
8 Clar-
ithromycin
200 mg
twice daily
38.5 52.9 0.0 76.2
Belot-
serkovskaya
2007
Russia 51 P, R 8 Azithro-
mycin (un-
known
dose)
NR NR NR NR
Black 2001 Multina-
tional
219 P, R, DB,
PC
6 Rox-
ithromycin
150 mg
twice daily
41.0 47.5 80.8 77.1
Brusselle
2013
Belgium 109 P, R, DB,
PC
26 Azithro-
mycin 250
mg
once daily
for 5 days
then three
times daily
53.0 (me-
dian)
38.5 100a 82.5
Cameron
2012
UK 77 P, R, DB,
PC
12 Azithro-
mycin 250
mg once
daily
44.6 48.1 85.7 78.3
Hahn
2006
USA,
Canada
45 P, R, DB,
PC
6 Azithro-
mycin 600
mg once
daily for 3
days then
weekly
47.7 48.9 80.0 NR
Hahn
2012
USA 75 P, R, DB,
PC
12 Azithro-
mycin 600
mg once
daily for 3
days then
weekly
46.6 32.0 72.0 NR
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Table 1. Summary characteristics of included studies at baseline (Continued)
He 2009 China 40 P, R, PC 12 Azithro-
mycin 250
mg twice
weekly
34.5 NR NR NR
Kamada
1993
USA 19 P, R, DB,
PC
12 Trolean-
domycin
250 µg
once daily
+ OCS
12.5 63.2 100 NR
Kapoor
2010
India 40 C, R, DB,
PC
6 Rox-
ithromycin
150 mg
once daily
NR NR NR NR
Kostadima
2004
Greece 75 P, R, DB,
PC
8 Clar-
ithromycin
250 mg
twice daily
or three
times daily
43.7 47.1 100 85.3
Kraft 2002 USA 55 P, R, DB,
PC
6 Clar-
ithromycin
500 mg
twice daily
33.4 49.1 32.7 69.3
Nelson
1993
USA 75 P, R, DB,
PC
52 Trolean-
domycin
250 mg
once daily
+ OCS
NR 33.3 0 NR
Piacentini
2007
Italy 16 P, R, DB,
PC
8 Azithro-
mycin
10mg/kg
once daily
3 days per
week
13.4 75 100 78.9
Shoji 1999 Japan 14 C, R, DB,
PC
8 Rox-
ithromycin
150 mg
twice daily
39.6 42.9 0.0 75.0
Simpson
2008
Australia 45 P, R, DB,
PC
8 Clar-
ithromycin
57.6 48.9 NRb 70.7
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Table 1. Summary characteristics of included studies at baseline (Continued)
500 mg
twice daily
Strunk
2008
USA 55c P, R, DB,
PC
30 Azithro-
mycin 250
or 500 mg
once daily
11.2 58.2 100a 101.9
Sutherland
2010
USA 92 P, R, DB,
PC
16 Clar-
ithromycin
500 mg
twice daily
39.4 43.5 NR 76.0
Wang
2012
China 45 P, R, PC 8 Clar-
ithromycin
500 mg
twice daily
NR NR NR NR
Wang
2014
China 58 P, R, PC 52 Azithro-
mycin 250
mg twice
weekly
29.0 NR NR NR
Xiao 2013 China 210 P, R, PC 12 Rox-
ithromycin
150 mg
twice daily
34.1 NR NR NR
Yan 2008 China 40 P, R, PC 4 Rox-
ithromycin
150 mg
twice daily
38.5 NR NR NR
Zhang
2013
China 60 P, R, PC 9 Azithro-
mycin 100
mg once
daily
NR NR NR NR
C: cross-over; DB: double-blind; NR: not reported; OCS: oral corticosteroids; P: parallel; PC: placebo-controlled; R: randomised.
aAll patients were taking LABA + ICS combination.
b82.2% were taking LABA + ICS combination.
c19 of these participants were not included in the review because they were randomised to a third group who received montelukast.
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A P P E N D I C E S
Appendix 1. Search methods up to May 2007
Trials were identified using the Cochrane Airways Group Specialised Register, which is derived from systematic searching of electronic
databases including the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE and CINAHL, and
handsearching of respiratory journals and meeting abstracts. All records in the Specialised Register coded as ’asthma’ were searched
using the following terms:
macrolide* OR clarithromycin OR troleandomycin OR erythromycin OR josamycin OR azithromycin OR roxithromycin
Review articles and bibliographies identified from these primary papers were surveyed for additional citations and RCTs.
The most recent search was run in May 2007.
Appendix 2. Sources and search methods for the Cochrane Airways Group Specialised Register
(CAGR)
Electronic searches: core databases
Database Frequency of search
CENTRAL (the Cochrane Library) Monthly
MEDLINE (Ovid) Weekly
EMBASE (Ovid) Weekly
PsycINFO (Ovid) Monthly
CINAHL (EBSCO) Monthly
AMED (EBSCO) Monthly
Hand-searches: core respiratory conference abstracts
Conference Years searched
AmericanAcademyofAllergy, Asthma and Immunology (AAAAI) 2001 onwards
American Thoracic Society (ATS) 2001 onwards
Asia Pacific Society of Respirology (APSR) 2004 onwards
British Thoracic Society Winter Meeting (BTS) 2000 onwards
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(Continued)
Chest Meeting 2003 onwards
European Respiratory Society (ERS) 1992, 1994, 2000 onwards
International PrimaryCareRespiratoryGroupCongress (IPCRG) 2002 onwards
Thoracic Society of Australia and New Zealand (TSANZ) 1999 onwards
MEDLINE search strategy used to identify trials for the CAGR
Asthma search
1. exp Asthma/
2. asthma$.mp.
3. (antiasthma$ or anti-asthma$).mp.
4. Respiratory Sounds/
5. wheez$.mp.
6. Bronchial Spasm/
7. bronchospas$.mp.
8. (bronch$ adj3 spasm$).mp.
9. bronchoconstrict$.mp.
10. exp Bronchoconstriction/
11. (bronch$ adj3 constrict$).mp.
12. Bronchial Hyperreactivity/
13. Respiratory Hypersensitivity/
14. ((bronchial$ or respiratory or airway$ or lung$) adj3 (hypersensitiv$ or hyperreactiv$ or allerg$ or insufficiency)).mp.
15. ((dust or mite$) adj3 (allerg$ or hypersensitiv$)).mp.
16. or/1-15
Filter to identify RCTs
1. exp “clinical trial [publication type]”/
2. (randomised or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. Animals/
10. Humans/
11. 9 not (9 and 10)
12. 8 not 11
The MEDLINE strategy and RCT filter are adapted to identify trials in other electronic databases.
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Appendix 3. Search strategy for Cochrane Airways Group Register
#1 AST:MISC1
#2 MeSH DESCRIPTOR Asthma Explode All
#3 asthma*:ti,ab
#4 #1 or #2 or #3
#5 MeSH DESCRIPTOR Macrolides Explode 1 2 3
#6 macrolide*
#7 azithromycin*
#8 clarithromycin*
#9 erythromycin*
#10 roxithromycin*
#11 spiramycin*
#12 telithromycin*
#13 troleandomycin*
#14 #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13
#15 #4 and #14
[In search line #1, MISC1 denotes the field where the reference has been coded for condition, in this case, asthma]
Appendix 4. Narrative of individual study results
Study ID Detail of results
Amayasu 2000 15 of the 17 patients improved their symptom score; 2 reported no improvement. The mean symptom
score decreased significantly after treatment with clarithromycin (1.64 SD 0.48 vs 0.88 SD 0.72 P < 0.05).
FVC and FEV1 did not show a significant variation during the time of clarithromycin therapy. This study
failed to confirm the bronchodilating effect of the macrolide. Blood eosinophil count as well as serum and
sputum ECP levels were significantly decreased after clarithromycin treatment (blood eosinophils 46.3 SD
6.9 vs 12.0 SD 2.4 P < 0.1, sputum eosinophils 90 SD 32 vs 11 SD 6 P < 0.05, both serum and sputum
ECP P < 0.05, 15.2 SD 7.3 vs 3.7 SD 1.5 and 1.7 SD 0.9 vs 0.4 SD 0.1, respectively).
Methacholine provocation test caused an obstructive reaction in all patients independently of the treatment.
PC20-methacholine was higher in the clarithromycin than in the placebo group (mean log PC20 metha-
choline was 2.96 SD 0.57 in clarithromycin vs 2.60 SD 0.51 in placebo P < 0.01).
No statistically significant association was found between increased PC20 methacholine and ECP levels.
No adverse reaction was reported during the treatment with clarithromycin.
The authors concluded that clarithromycin has not only antibacterial, but also an anti-inflammatory activity,
associated with a reduction of the eosinophilic infiltration in patients with asthma. It is able to improve
symptoms and bronchial hyperresponsiveness, but further trials are needed to investigate its clinical utility
Belotserkovskaya 2007 Only an abstract from the ERS congress 2007 is available for this study. Data are only partially reported.
No significant difference was reported for FEV1, PEF, rescue medications and symptoms between the
azithromycin and the placebo group. A subgroup analysis for the patients treated with azithromycin and
with serologic positivity for C. pneumoniae showed a statistically significant improvement from the baseline
for FEV1 and PEF (from 1.99 L to 2.25 L, P = 0.01, and from 305.1 to 348 L/min, P = 0.03 respectively)
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Black 2001 At the end of the 6 weeks of treatment, the increase of the mean values of morning PEF was significantly
higher in the treated group (14 L/min) compared to the placebo group (8 L/min). There was a subsequent
increase of the morning PEF values in both groups over the following 6 months after the end of treatment,
where the improvement over baseline was 18 L/min in the roxithromycin group, compared to 12 L/min in
the placebo group (P = NS). For evening PEF values, roxithromycin significantly improved PEF values (15
L/min vs 3 L/min in the placebo group) at the end of the treatment (P = 0.02), but not at later time points.
Both the daytime and the nighttime symptom scores showed a non-significant improvement in the treated
group compared to the placebo group over the 6-month study period.
There was a non-significant trend for improved AQLQ score with treatment. No statistically significant
difference was recorded for the daytime and nighttime symptoms scores.
No difference was found for rescue medications or for Chlamydophila antibody titres measured during the
study.
No difference was reported for side effects between the 2 groups. Only mild and reversible liver function
test alterations were recorded in 2 patients treated with roxithromycin.
The authors concluded that the (not statistically significant) trend of improvement of pulmonary function
test as seen in the 3 months following end of treatment in the roxithromycin group compared to the placebo
group, suggest that the effect of themacrolide therapy on PEF values could be due more to the antimicrobial
effect than to the antiinflammatory effect of the drug, and that the onset time and persistence of the effect
could be due to a suppression more than a eradication of the C. pneumoniae infection. The authors also
suggested a study with the use of 2 antibiotics active against C. pneumoniae.
Brusselle 2013 No difference was found between the treatment arms in the primary endpoint (i.e. rate of severe asthma
exacerbations, defined as need for hospitalisation, need for systemic steroids for at least 3 days or ER visits)
or in lower respiratory tract infections requiring antibiotics
No effect of azithromycin compared with placebo was demonstrated after 26 weeks for lung function (FEV1
and morning and evening PEF), or for the ACQ. The AQLQ score was significantly improved after 26
weeks from the baseline in the azithromycin group, but not in the placebo group; no significant difference
were found between the azithromycin and placebo group when comparing the AQLQ score after 26 weeks
of treatment
No differences were found in the rate of adverse events in the azithromycin and placebo group over the
study. A significantly higher proportion of patients treated with azithromycin compared with the patients
treated with placebo had macrolide resistant strains of streptococci at the end of the study (87% vs 35%, P
< 0.001)
A predefined subgroup analysis for the main outcome showed a statistically significant reduction in the rate
of exacerbations in patients with non-eosinophilic severe asthma (defined as blood eosinophils ≤ 200/µL)
treated with macrolides vs the same type of patients receiving placebo (0.44 primary endpoint rate, 95%
CI 0.25 to 0.78 vs 1.03 primary endpoint rate, 95% CI 0.72 to 1.48, P = 0.01 respectively). Conversely,
a higher primary endpoint rate was recorded in the group treated with azithromycin (0.96, 95% CI 0.66
to 1.41) compared with the placebo group (0.50, 95% CI 0.28 to 0.88) among the patients with severe
asthma and blood eosinophils > 200/µL)
Cameron 2012 The study did not show any significant difference between the arm treated with azithromycin and the
placebo group
The primary outcome (change from the baseline of the morning PEF) was not different in the 2 treatment
arms, with a mean difference of -10.3, 95%CI -47.1 to 26.5 L*min−1, P = 0.58. No difference was recorded
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for FEV1 at 12 weeks (pre-albuterol, 2.41 ± 0.77 L/s in the azithromycin groups vs 2.46 ± 0.75 L/s in
the placebo group. P = NS) or for the bronchial hyperreactivity (0.20 ± 1.52 Log PC20 mg/mL in the
azithromycin groups vs 0.19 ± 1.29 Log PC20 mg/mL in the placebo group, P = NS).
No significant effect of macrolides was observed for the use of rescue medications (2.7 ± 2.5 times/day in
the azithromycin group vs 3.0 ± 4.0 times/day in the placebo group, P = NS), for the scores of ACQ (1.75 ±
0.83 vs 1.58 ± 0.96, P = NS), AQLQ (5.2 ± 1.06 vs 5.42 ± 1.31, P = NS) or for the count of eosinophils in
the induced sputum (10.3 ± 20.1*104 vs 6.8 ± 13.9*104 , P = NS, in the azithromycin and placebo group,
respectively) after the 12-week study period
No adverse events were recorded in either of the treatment arms during the study
Hahn 2006 No significant difference was observed at 3 months after the completion of the 6 week-treatment for the
outcomes Juniper AQLQ (0.59 ± 0.8 vs 0.34 ± 1.0, P = NS) and rescue medications (0.43 ± 1.8 times/
day vs − 0.16 ± 1.3, P = NS) in the azithromycin group compared with the placebo group, respectively.
Symptoms and daily activities, recorded with a homemade scale from 0 = no symptoms to 4 = worse than
ever, were significantly improved in patients treated with azithromycin compared with placebo (0.55 ± 0.7
vs − 0.13 ± 0.9, P = 0.04)
3 patients per group withdrew consent during the study, while 1 patient in the azithromycin group discon-
tinued the study
No adverse events were recorded among the patients in the azithromycin group. 1 serious adverse event
occurred in the placebo group, with a patient who died for asthma-related causes
Hahn 2012 Only data from the randomised treatment arm and the placebo arm were considered in the systematic
review/meta-analysis, while the open label arm was excluded. Of 304 screened patients, 97 (32%) were
enrolled: 38 were randomised to azithromycin, 37 to placebo and 22 were allocated to the elected open
label treatment
No significant difference was observed for severe exacerbations across the study groups, but rates in the
different groups were not reported
No significant difference was observed for symptoms with a home scale from 0 = no symptoms to 4 = worse
than ever (− 0.31 ± 0.74 vs − 0.48 ± 1.16, P = NS), for the ACQ score (− 0.40 ± 0.8 vs − 0.41 ± 1.1, P
= NS) and in the Juniper AQLQ (0.67 ± 1.10 vs 0.50 ± 0.95) between the randomised azithromycin and
placebo group, respectively, 1 year after randomisation
Withdrawal was high and quite uneven between groups (19 patients (50%) and 12 (32.4%) at the 12-
month-follow-up in the randomised azithromycin and placebo groups, respectively)
One subject in the placebo group discontinued the study because of acute coronary syndrome; another
patient in the placebo group discontinued the study because of side effects. Mild side effects were common
among patients treated with azithromycin (nausea, 33% vs 9% for placebo, stomach pain, 42% vs 12% for
placebo and diarrhoea, 42% vs 15% for placebo), but none of them discontinued medications because of
the side effects
Kamada 1993 A significant glucocorticoid dosage reduction was recorded in all 3 groups. The maximum tolerated per-
centage dosage reductions were 80% ± 6% in the troleandomycin-methyl prednisone group (P < 0.001)
, 55% ± 8% (P < 0.001) for the troleandomycin-prednisone group, 44% ± 14% (P = 0.04) for methyl
prednisone group. A significant difference was present only between troleandomycin-methyl prednisone
group and methyl prednisone group.
No statistically significant difference was reported for days of supplemental prednisone for exacerbations.
Symptom score was reduced by nearly 50% in patients receiving troleandomycin-methyl prednisone (P
= 0.03). There were no significant differences in the other two groups. Pulmonary function tests were
slightly reduced in all groups, with a significant reduction of pre-bronchodilator FEV1 and FEF25 75
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in the troleandomycin-prednisone group (P = 0.03 and P = 0.01, respectively). Methacholine PC20 was
significantly reduced only in the troleandomycin-methyl prednisone group and slightly increased in the
troleandomycin-prednisone group, but the difference may be a reflection of glucocorticoid dosage taper
and supplemental prednisone before the final evaluation.
Safety aspects: 13 patients received troleandomycin. 1 patient in the troleandomycin-prednisone group
experienced an elevation of liver enzymes that was resolved by the discontinuation of troleandomycin.
Another patient, in the troleandomycin-methyl prednisone group, reported amild elevationof liver enzymes,
which resolved spontaneously without discontinuation of the treatment. No significant alteration of serum
and urine cortisol concentrations were observed, whereas an increase was observed in the methyl prednisone
group. Bone density was unchanged in all groups. A slightly decrease (NS) in bone density was observed
in the two groups receiving troleandomycin. One patient, in the troleandomycin-prednisone group, was
severely osteopenic before the start of the study and experienced a vertebral compression fracture that
was attributed to her previous glucocorticoid exposure. Another patient in the troleandomycin-prednisone
group developed marked striae on the arms and trunk. She was also affected by Marfan syndrome.
The authors concluded that, despite the absence of a control group with only prednisone and the poor
number of subjects for each group, some conclusions could be drawn from this study: it is not possible to
improve lung function by tapering the steroid dose; the only goal reached is to keep the same level of lung
function when reducing the dose of steroids, without severe adverse effect
Kapoor 2010 This study was presented in the form of abstract at the ERS Congress 2010 in Barcelona
A significant improvement from the baseline was reported for the ACT score in both the roxithromycin
and the placebo group, but no difference was observed when comparing the improvements between the 2
groups after the 6 weeks of treatment (2.68 ± 3.17 vs 1.80 ± 2.83, P = NS in the roxithromycin and in the
placebo group, respectively). No significant difference between the groups were reported for FEV1 at the
end of the study.
Only very limited information on patients’ characteristics and randomisation are available. No data are
reported for withdrawal or adverse events, and data on lung function and impulse oscillometry are described
only as not significantly different in the 2 groups
Kostadima 2004 A significant increase of the FEV1% was reported only in the group B (from 85±13 at the baseline to 88±12
at the end of the study period, P<0.05). In the other 2 groups the predicted values were 85±14 and 86±14
at the baseline and 85±12 and 88±15 in group A and C, respectively, differences not statistically significant.
Compared to the baseline, there was a significant increase in the median PD 20 in groups A and B (receiving
the macrolide) but not in the placebo group. Median (interquartile range) in the 3 groups were before and
after the treatment were: group A: 0.3 (0.1-1) and 1.3 (0.6-2) mg (P<0.001); group B: 0.4 (0.1-0.9) mg
(P<0.001); and group C: 0.4 (0.1-0.9) and 0.3 (0.1-0.6) mg (P=NS).
No side effects were clearly reported, but a patient in the group B withdrawn for a gastrointestinal disorder
(no further details were reported). Cortisol levels were measured in 40 patients, no alteration was found at
the baseline and after the treatment with the macrolide
Kraft 2002 Out of 55 patients included in the study, 3 were not randomised due to scheduling difficulties (n = 1) and
noncompliance (n = 2). The clarithromycin group included 26 randomised patients, as did the control
group. Fourteen patients in the treatment group and 13 patients in the placebo group showed a positive
PCR for M. pneumoniae or C. pneumoniae at the baseline on samples obtained via bronchoscopy.
No change in the FEV1 mean values between clarithromycin and placebo was reported at the end of the
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treatment (2.64 ± 0.14 L vs 2.69 ± 0.16, respectively, P = 0.75). A subanalysis for PCR status the subjects
with a positive PCR for M. pneumoniae orC. pneumoniae showed a significant increase from their baseline
after the therapy with clarithromycin (from a FEV1 mean value of 2.50 ± 0.16 to 2.69 ± 0.16, P = 0.05, n =
14), whilst this change was not observed in subjects with a positive or negative PCR who received placebo
(data are not reported in the paper) or with a negative PCR who received the macrolide (baseline FEV1
mean value 2.59 ± 0.24 L vs 2.54 ± 0.18 L after the treatment, P = 0.85, n = 12)
The study was also designed to investigate the modulation of inflammatory cytokines in BAL and bronchial
biopsies during the treatment with clarithromycin. A significant reduction in the expression of TNF-alpha,
IL-5 and IL-12 mRNA in BAL and TNF-alpha in airways tissue among the PCR-positive patients treated
with macrolides and the PCR-negative patients receiving clarithromycin, showed a significant reduction in
the expression of TNF-alphaand IL-12 mRNA in BAL and TNF-alpha in airways tissue. No significant
difference in the cytokines expression was noted among subjects receiving placebo
It is unclear why the patients underwent a sinus CT evaluation if they were not affected by chronic sinusitis
and if one of the exclusion criteria was a history of upper airways infection in the last 3 months before the
study
No data on adverse events were available.
Nelson 1993 Significant reduction in the requirement for hospitalisation and steroid boost relative to the year before the
study were reported in both active and placebo groups. Similar results were reported during the 2 years of
follow-up, with non-significant differences between the 2 groups. Data were expressed as rate/year, not as
number of events. The authors remarked that the tapering of steroid dose was performed only in situations
of complete symptom control and that symptom control was not an evaluable outcome.
Corticosteroid dose: themean steroid dose at enrolmentwas not significantly different between the 2 groups.
The mean dose reported in the placebo group during the year preceding the study entry was significantly
higher than in the troleandomycin group (22.8 mg/day, SD 1.9 mg/day vs 17.6 mg/day SD 1.5 mg/day P
= 0.02). A significant reduction from the previous corticosteroid usage was reported for the lowest stable
dose in both groups, with troleandomycin treated patients reaching a lower dose (10.4 mg/day SD 1.3 mg/
day vs 6.3 mg/day SD 1.3 mg/day P = 0.03). Neither the 1-year nor the 2-year reduction of the dose was
significantly different in the 2 groups.
Corticosteroid effects: eosinophil counts were significantly increased at the time of the 1-year evaluation in
both groups. Similarly, the 60-minute stimulated cortisol levels rose during the study, and after 1 year the
difference was significant in both groups, but not between groups.
Dual-photon densitometry of the L2-4 vertebrae showed a continued decline in both groups of bone density
when adjusted for age-matched controls. The mean decline over 1 and 2 years was twice as great, but
significant only in the troleandomycin group (1 year P = 0.01, 2 years P = 0.001).
Significant differences between the 2 groups were reported for the following 3 parameters:
Mean IgG level decreased in the troleandomycin group, and this change was not observed in the placebo
group (2 years P = 0.03).
Fasting blood sugar increased in the troleandomycin group and decreased in the placebo group (2 years P
= 0.02).
Mean cholesterol level increased in the troleandomycin group, although not significantly; it was lower in
the placebo group after 1 and 2 years (P = 0.03 and P = 0.01, respectively), with a significant difference
between the 2 groups (P = 0.02 and P = 0.03 in the 1- and 2-year groups, respectively).
Methacholine challenge was performed in only 11 patients in the placebo and in 13 in the treatment
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group. The dose producing a 20% fall in FEV1 rose in the troleandomycin group, indicating less airway
responsiveness (0.55 mg/mL in the placebo vs 1.86 mg/mL in the macrolides group, P = 0.08).
3 subjects died during the study, 2 in the treated group and 1 in the placebo group, none for asthma
Number of dropouts at 1 year of the study were higher in the placebo group (n = 11, 28.9%) than in the
treatment group (n = 7, 18.9%).
The authors highlighted the importance of adequately educating the patients regarding the use of anti-
asthma drugs, especially steroids. Although the study showed a significant difference in the lower stable
dose reached in the troleandomycin group, the increase in indicators of side effects such as cholesterol and
fasting blood sugar, and a less significant reduction in the bone densitometry, did not confirm the utility of
the steroid sparing effect of troleandomycin but showed a detrimental action with increasing the potential
for adverse effects of steroid treatment
Piacentini 2007 8 patients were randomised to receive azithromycin and 8 were randomised to the control group
The study did not show any statistically significant variation for FEV1 within and between the study groups
(azithromycin FEV1 %of reference value 73.5 ± 12.90 at time point 0 and 74.62 ± 9.76 after the treatment,
P = NS; placebo FEV1 % of reference value 84.25 ± 9.58 at time point 0 and 86.00 ± 9.85, P = NS,
comparison between azithromycin and placebo group at the end of the study not statistically significant)
Bronchial hyperresponsiveness was assessed with a hypertonic saline challenge and expressed not as PD15
but as dose-response slope (DRS), reflecting the fall of FEV1 per unit of substance inhaled. A significant
reduction from the baseline in the DSR was observed in the azithromycin group at the end of the study (2.
75 ± 2.12 to 1.42 ± 1.54, P = 0.02), but not in the placebo group (1.48 ± 1.75 to 1.01 ± 1.38, P = NS).
No differences were shown with between-group comparisons
Sputum analysis was conducted in 6 patients in the treatment group and in 7 patients in the placebo
group. The percentage of neutrophils in the sputum was significantly decreased from the baseline in the
azithromycin group (10% ± 5% to 2.2% ± 2.4%, P < 0.01) but not in the placebo group (7.2% ± 4.2% to
3.2% ± 3.6%, P = NS). No differences were shown with between-group comparisons
This study did not report data on dropouts and adverse events
Shoji 1999 Symptom score significantly decreased after roxithromycin treatment (1.63 ± 0.48 vs 0.87 ± 0.70 P < 0.05)
.
No statistically significant differences were observed in the FEV1 between roxithromycin and placebo treated
patients after the 8 weeks (2.37 ± 0.30 to 2.25 ± 0.26 respectively, P = NS) or for the provocation test with
sulpyrine (PC20 sulpyrine 1.18 ± 0.40 in the roxithromycin group, 1.15 ± 0.43 for the placebo group at
the end of the study, P = NS).
No difference was found in the leukotriene E4 elimination in the urine after the treatment within and
between groups.
Mean ECP and eosinophils count both in serum and sputum showed a significant decrease after the 8 weeks
period of treatment with the antibiotic (blood eosinophils from 43.36 ± 7.3 to 12.4 ± 2.3*104/mL, P < 0.
01; sputum eosinophils from 94 ± 28 to 10 ± 6*104/mL; serum ECP 15.8 ± 6.3 to 3.6 ± 1.4 mg/L, P < 0.
05; sputum ECP 1.8 ± 0.4 to 0.4 ± 0.1 mg/L P < 0.05)
Dropouts were not reported. None of the patients reported any adverse effects
Simpson 2008 This study was designed and powered primarily to detect a difference in the IL-8 expression in sputum
supernatants of patients with refractory asthma after treatment with macrolides. Results were reported as
median and interquartile range for most of the descriptive statistics
The levels of IL-8 were significantly reduced from the baseline within the clarithromycin group, with 6.
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6 ng/mL (2.7 to 11.9) before and 3.9 ng/mL (1.8 to 5.4) after the treatment (P = 0.001). A statistically
significant difference (with a cut-off point of 0.05 used to determine significance) was also observed when
IL-8 levels in the treatment group at the end of the study were compared with the results in the placebo
group, where 6.3 ng/mL (3.1 to 17.3) and 6.4 ng/mL (3.7 to 11.3) were measured at the beginning and at
the end of the study period, respectively
The number of neutrophils in the sputum was significantly reduced (P < 0.04) in the clarithromycin group
from the baseline at the end of the treatment, from 142.9*104/mL to 66.7*104/mL, respectively, but no
significant difference was found when comparing the results with the placebo group
No effect of clarithromycin was demonstrated on FEV1 % within the treatment arm (73.6 ± 15.8 at time
point 0 and 74.6 ± 17.1 at the end of treatment period, P = NS) or in comparison with the placebo group
(P = NS)
No effect of clarithromycin was demonstrated on bronchial hyperresponsiveness within the treatment arm,
with dose-related slope in the hypertonic saline challenge 1.8 (0.6 to 6.4) at time points 0 and 1 (0.5 to 4.
2) at the end of treatment period, P = NS, or in comparison with the placebo group (P = NS)
The total score for the AQLQ was significantly improved in the clarithromycin group from the baseline
(score 5.5, IQR 4.8 to 6.4) after the treatment period (score 6.2, IQR 5.4 to 6.6, P = 0.014), but not in
comparison with the placebo group (score 6.4, IQR 5.2 to 6.7 at time point 0 and score 6.4, IQR 5.7 to
6.8, P = NS both within the placebo group and for the comparison with the treatment arm)
The total asthma control score was not significantly improved in the clarithromycin group from the baseline
(score 1.6 ± 0.6) after the treatment period (score 1.3 ± 0.7, P = NS); no difference was found in the
comparison with and within the placebo group (score 1.3 ± 1.0 at time point 0 and score 1.2 ± 0.8, P = NS
both within the placebo group and for the comparison with the treatment arm)
A predefined subanalysis showed that most of the significant differences for IL-8 levels,MMP-9 and AQLQ
were driven by the effect of macrolides in a subgroup of patients with non-eosinophilic asthma defined as
proportion of neutrophils in induced sputum ≥ 61%
Strunk 2008 This study was designed to test a potential inhaled steroid-sparing effect of azithromycin compared with
an arm with montelukast and a placebo arm, in children with persistent to severe asthma. After a run-in
period of 6 weeks, when patients were treated with salmeterol and an increasing dose of inhaled budesonide
to obtain good control of asthma, patients were randomised to azithromycin or montelukast or placebo,
holding the same dose of inhaled steroids for 6 weeks. Inhaled steroids were then reduced according to a
predefined protocol every 6 weeks
Only 55 (19%) of 292 patients enrolled for inclusion in the study reached the randomisation. Out of the
55 patients randomised, 35 (63.6%) reached inadequately controlled status of asthma within a median of
5.1 weeks (range 2.4 to 23.4 weeks) after randomisation. The study was prematurely terminated by the
Data Safety Monitoring Board
No difference was found in time regarding inadequate control among the 3 groups (median (weeks, 95%
CI)): azithromycin,
8.4 (4.3, 17.3); montelukast, 13.9 (4.7, 20.6); placebo, 19.1 (11.7, infinity). A futility analysis with the
available data indicated that the study might have shown negative results even if the planned sample size of
210 children was reached
PCR for C. pneumoniae or M. pneumoniae showed no evidence of infection in 140 samples collected from
the 55 patients randomised to the treatment arms
Sutherland 2010 The study investigated the role of clarithromycin in adults with mild-to-moderate persistent asthma not
optimally controlled by inhaled steroids and analysed the results according to the PCR status for M.
pneumoniae and C. Pneumonia on bronchoscopy samples. A sample size of at least 72 patients for PCR
status was required to achieve a 90% power to detect a difference of 0.5 in the primary outcome, the ACQ
score
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Of 253 patients meeting the criteria for inclusion in the study, only 92 were randomised in the 2 treatment
arms (clarithromycin and placebo) due to suboptimal asthma control during the 4-week run-in period.
Among them, 12 (13%) demonstrated a positive PCR forM. pneumoniae orC. pneumoniae, while 80 (87%)
showed a negative PCR. The original purpose to reach 72 patients with evidence of infection was judged
as not feasible, and further enrolment stopped
The ACQ score was not significantly improved in any comparison within and between the treatment arms
and PCR status at the end of the study period:
- difference in ACQ score between the clarithromycin and placebo groups irrespective of PCR status (n =
92): 0.2 ± 0.2, P = 0.2;
- difference in ACQ score between the clarithromycin and placebo groups in patients with a positive PCR
status (n = 12): 0.3 ± 0.5, P = 0.6;
- difference in ACQ score between the clarithromycin and placebo groups in patients with a negative PCR
status (n = 80): 0.2 ± 0.2, P = 0.3
FEV1 (pre-albuterol) was not significantly improved in any comparison at the end of the study period:
• difference in FEV1 (L) between the clarithromycin and placebo groups irrespective of PCR status (n
= 92): 0.0 ± 0.1, P = 0.8;
• difference in FEV1 (L) between the clarithromycin and placebo groups in patients with a positive
PCR status (n = 12): 0.4 ± 0.2, P = 0.9;
• difference in FEV1 (L) between the clarithromycin and placebo groups in patients with a negative
PCR status (n = 80): − 0.2 ± 0.1, P = 0.8.
Similar results were obtained for FEV1 %, morning and evening PEF and rescue medications, with no
statistically significant differences shown for any within and between groups analyses, even in the PCR
status comparisons
Bronchial hyperresponsiveness was significantly improved by clarithromycin compared to placebo in the
whole population and in the PCR negative groups, but not among the PCR positive patients:
• difference in PC20 doubling dose between the clarithromycin and placebo groups irrespective of
PCR status (n = 92): + 1.2 ± 0.5, P = 0.01;
• difference in PC20 doubling dose between the clarithromycin and placebo groups in patients with a
positive PCR status (n = 12): + 0.9 ± 1.8, P = 0.6;
• difference PC20 doubling dose between the clarithromycin and placebo groups in patients with a
negative PCR status (n = 80): + 1.2 ± 0.5, P = 0.02.
The incidence of adverse events was not different between the clarithromycin and placebo group; no severe
adverse event was recorded
ACQ: Asthma Control Questionnaire; ACT: Asthma Control Test; AQLQ: Asthma Quality of Life Questionnaire; BAL: bron-
choalveolar lavage;CI: confidence interval;CT: computed tomography;DRS: dose-response slope; ECP: eosinophil cationic protein;
ER: emergency room; ERS: European Respiratory Society; FEF25-75: the average forced expiratory flow during the mid (25%
to 75%) portion of the FVC; FEV1 : forced expiratory volume in one second; FVC: forced vital capacity; IgG: immunoglobulin
G; IL: interleukin; MMP: matrix metallopeptidase; NS: not significant; PEF: peak expiratory flow; PC20 or PD20 : provocative
concentration (or dose) causing a 20% fall in forced expiratory volume in 1 second (FEV1); PCR: polymerase chain reaction; SD:
standard deviation;TNF-alpha: tumour necrosis factor alpha.
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F E E D B A C K
Feedback concerning presentation of data, 16 April 2016
Summary
As primary author of two RCTs included in your recent review of macrolides for asthma, I would like to question the presentation of
data from one of my studies (Hahn 2006) that I feel may affect the interpretation of review findings for two outcomes.
The symptom scale forest plot (Analysis 1.3) placed the central point for overall symptoms for our RCT on the “favors placebo” side
whereas our results favored macrolide, as stated in our abstract and as illustrated in our Figure 2. It is possible the problem arose during
the examination of Table 2 in which we described a symptom change score difference with a (+) result indicating improvement, as
noted in our footnote. We also reported that the overall symptom score change favoring azithromycin was statistically significant (0.68,
95% CI 0.1 to 1.3).
The AQLQ forest plot (Analysis 1.5) likewise placed the central point for AQLQ change score for our RCT (2) on the “Favors placebo”
side whereas our results favored macrolide, as stated in our abstract. In this case the sign of the positive result was not changed because a
positive score already reflected improvement. The review accurately presented the midpoint data from our Table 2 but report different
confidence intervals.
I advocate for Analyses 1.3 & 1.5 to be amended in the interest of correct data.
Highest regards for the work you do,
Dr. Hahn.
Reply
Dear Dr Hahn,
We are very grateful for your helpful feedback regarding the accuracy of data pertaining to your study (Hahn 2006).
Regarding Analysis 1.3, we agree data from your study have been misinterpreted, causing the effect to lie in the opposite direction. This
has now been amended in the review to correctly represent your symptom scale data in the meta-analysis, and in the interpretation of
the results. There may be differences between the methods we have used and your own which make the data look slightly different.
For example, we had to use a standardised mean difference analysis because the scales were not the same across studies, meaning your
raw data were transformed and displayed as standard deviation units. Importantly, the pooled result for symptom scales now favours
macrolide.
Regarding Analysis 1.5, while the effect for Hahn 2006 lies to the right of the line of no difference, this indicates ‘favours macrolide’
on the forest plot. As is standard practice for scales where higher scores indicate improvement, the labels of the plot were swapped to
represent correctly the direction of effect. As above, the confidence intervals may differ slightly as a result of the method of analysis
used. We used the mean change scores and standard deviations presented in Table 2 (0.59 (0.8) n = 19 azithromycin; 0.34 (1.0) n = 17
placebo), entered in a generic inverse variance (GIV) analysis in RevMan. We have not altered this analysis but hope this clarification
satisfies you that these data have been interpreted correctly.
Many thanks again for the time and consideration taken to submit these comments.
Kayleigh Kew on behalf of the authors for the review.
Contributors
David L Hang, MD MS email: dlhahn@wic.edu, Affiliation: Wisconsin Research & Education Network (WREN)
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WH A T ’ S N E W
Last assessed as up-to-date: 15 April 2015.
Date Event Description
13 May 2016 Feedback has been incorporated Hahn 2006 data corrected in Symptom scales analysis 1.3 after receiving feedback.
New pooled result carried through text. Overall conclusions not affected
H I S T O R Y
Protocol first published: Issue 1, 2000
Review first published: Issue 3, 2001
Date Event Description
15 April 2015 New citation required and conclusions have changed Sixteen newRCTs have been included.No real advantage of
the use of macrolides in patients with asthma was demon-
strated
The review was redrafted for this update.We added a ’Sum-
mary of findings’ table and used the current methodology
recommended byCochrane.We re-extracted data from pri-
mary studies for the studies included in the previous ver-
sion, including applying the new ’Risk of bias’ tool
15 April 2015 New search has been performed New literature search run
7 August 2008 Amended Converted to new review format.
6 June 2005 New citation required and conclusions have changed Substantive amendment
C O N T R I B U T I O N S O F A U T H O R S
Kayleigh Kew: data extraction, entry and analysis, drafting of the review.
Krishna Undela: data extraction, drafting of the review.
Ioanna Kotortsi: data extraction.
Giovanni Ferrara: data extraction, entry, interpretation, and drafting of the review.
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• Kayleigh Kew, UK.
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External sources
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
This update of the review has been brought up to date with current methodology, which meant changing some of the methods from
those stated in the original protocol. GRADE was used to assess the quality of the evidence for the primary outcomes, and a ’Summary
of findings’ table has been added. Methods for data synthesis have been explained in more detail, and we replaced Jadad with the
Cochrane ’Risk of bias’ tool (Jadad 1996).
The planned subgroup and sensitivity analyses were not appropriate given the small number of studies in the analyses.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Anti-Bacterial Agents [∗therapeutic use]; Anti-Inflammatory Agents [∗therapeutic use]; Asthma [∗drug therapy]; Chronic Disease;
Disease Progression; Macrolides [∗therapeutic use]; Randomized Controlled Trials as Topic
MeSH check words
Adult; Child; Humans
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